

UNCLASSIFIED

AD NUMBER
ADB253635
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 99. Other requests shall be referred to US Army Medical Research and Materiel Command, Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 1 Jun 2001.

THIS PAGE IS UNCLASSIFIED

AD _____

GRANT NUMBER DAMD17-96-1-6146

TITLE: Characterization of Breast Cancer Cell Death Induced by Interferons and Retinoids

PRINCIPAL INVESTIGATION: Dhan Kalvakolanu, Ph.D.
Edward Hofmann

CONTRACTING ORGANIZATION: University of Maryland at Baltimore
Baltimore, Maryland 21201

REPORT DATE: July 1999

TYPE OF REPORT: Annual

PREPARED FOR:

U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 2

20000516 103

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-96-1-6146

Organization: University of Maryland at Baltimore

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Mr. Edward R. Hofmann

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1999	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 98 - 30 Jun 99)	
4. TITLE AND SUBTITLE Characterization of Breast Cancer Cell Death Induced by Interferons and Retinoids			5. FUNDING NUMBERS DAMD17-96-1-6146	
6. AUTHOR(S) Dhan Kalvakolanu, Ph.D. Edward Hofmann				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Maryland at Baltimore Baltimore, Maryland 21201			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, MD 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Interferons (IFNs) and retinoic acid (RA) are potent biological response modifiers that inhibit transformed cell growth. In tumor cells resistant to either IFN or RA, combination of both agents causes stronger growth inhibition. Using athymic nude mouse models and <i>in vitro</i> assays we have previously shown that IFN- β /RA combination causes death of human breast carcinoma cells. To identify genes that participate in IFN- β /RA induced death pathways, we employed a genetic strategy called Suppression of Mortality by Antisense-Rescue Technique (SMART). Rescue of genes was possible by positive growth selection of cells treated with IFN- β /RA after transfection with antisense cDNA expression libraries. Using this system we have isolated several candidate genes termed Genes associated with Retinoid-Interferon induced Mortality (GRIM). Previously, we have demonstrated that GRIM-12 is identical to human thioredoxin reductase (TR). In this report we demonstrate that GRIM-12 overexpression suppresses cell growth. Growth suppression is mediated by increased enzyme activity and is enhanced by IFN- β /RA combination. Furthermore, we have characterized an interface domain (ID) that inhibits the growth suppressive effects of IFN- β /RA combination but not other activators of growth suppression. Interference with TR enzyme activity by ID expression led to growth promotion in the presence of IFN- β /RA combination. We have demonstrated that this domain is able to associate with full-length GRIM-12 <i>in vitro</i> . Thus, dimerization may be important for GRIM-12 mediated growth suppression. We have confirmed that GRIM-1 is a novel gene. In this report we use 5'RACE to isolate a full-length cDNA. Northern analysis revealed that many GRIM-1 transcripts are expressed in many human and mouse tissues in a tissue specific manner. GRIM-1 is able to encode three proteins <i>in vitro</i> .				
14. SUBJECT TERMS Breast Cancer, interferon, apoptosis, retinoids, thioredoxin reductase.			15. NUMBER OF PAGES 31	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ ____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

SPH ____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

SPH ____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 7/28/99

PI - Signature Date

Table of Contents

FRONT COVER	1
REPORT DOCUMENTATION PAGE	2
FOREWORD	3
TABLE OF CONTENTS	4
INTRODUCTION	5
BODY	5
APPENDICES	9

Introduction:

This training fellowship was awarded to a pre-doctoral student, Edward R. Hofmann, at the University of Maryland School of Medicine. Research data generated from this study will be submitted as a Ph. D. thesis in the future.

Interferons (IFNs) and retinoic acid (RA) are potent biological response modifiers that inhibit transformed cell growth. IFNs use the JAK/STAT signaling cascade to regulate IFN-stimulated genes, which mediate growth suppression. Retinoids bind to nuclear receptors, which act as transcription factors to regulate genes associated with cell growth and differentiation. In breast tumor cells resistant to IFN or RA, a combination of both agents synergistically inhibits cell growth. Using athymic nude mouse models and in vitro systems we have shown earlier that IFN- β /RA combination induces programmed cell death (PCD) of human breast carcinoma cells. PCD induced by IFN β /RA combination does not appear to be regulated exclusively by known pathways of apoptosis. We used a genetic approach called Suppression of Mortality by Antisense Rescue Technique (SMART) to identify novel members of the IFN/RA combination induced PCD pathway. Total cell cDNA libraries, from breast tumor cells treated with IFN/RA combination, were expressed in an antisense fashion in HeLa cells. Following transfection of these libraries, the cells were selected with lethal doses of IFN- β /RA combination and screened for resistance to IFN/RA induced PCD. Using this technique we have isolated several candidate genes termed Genes associated with Retinoid-IFN Induced Mortality (GRIM). Previously, we identified one of these genes, GRIM-12. GRIM-12 is identical to human thioredoxin reductase (TR). IFN/RA combination stimulates the post-transcriptional expression of GRIM-12. The enzymatic activity of TR is essential for mediating cell death. Dominant negative mutants were constructed to characterize this gene further. Another gene, GRIM-1, was identified as a novel gene. Northern analysis demonstrated the IFN/RA combination induces two GRIM-1 transcripts. cDNA λ phage libraries were screened in attempt to clone the full length cDNA but failed to obtain a clone of equal length of the detected transcripts.

Body:

Experimental Approach:

In order to keep this report concise, new data for GRIM-12 will be kept brief and major accomplishments will be mentioned in the Body and Appendices. For a detailed description of GRIM-12 data, the reader should refer to the included manuscript; "Thioredoxin Reductase Mediates...Retinoic Acid". GRIM-12 mutants were generated as described previously and effects of their expression on cell death induced by various drugs will be analyzed. A 171 amino acid region at the carboxy-terminal end of GRIM-12 is thought to be involved in dimer formation based on its homology to other known reductases. We will express this domain as well as full length GRIM-12 in bacterial expression systems and analyze their interactions via pull-down assays with affinity columns. Finally we will look at the effects of GRIM-12 overexpression in relation to

growth rates, enzyme activity and sensitivity to IFN- β /RA combination induced cell death. In order to obtain a full-length clone of GRIM-1, we will employ 5' rapid amplification of cDNA ends (5' RACE). After obtaining a full-length clone, we will use DNASIS sequence software to identify an open reading frame. Databases such as BLAST and Swissprot will be used to identify identical or homologous proteins and programs such as MOTIF and BLOCKS will be used to search for functional properties of the protein. In vitro transcription and translation with rabbit reticulate lysates will be used to confirm the open reading frame and expression of an encoded protein. Growth assays will be performed on cells expressing the antisense GRIM-1 episome in order to verify its role in cell growth control. Multiple tissue northern blots will be used to analyze the expression of GRIM-1 transcripts. Finally, we will use the pET32 bacterial expression system to express the GRIM-1 protein in order to use for antibody production.

Results:

Effects of overexpression of GRIM-12 on cell growth: Deletion mutants were constructed and the expression of various functional domains was analyzed by northern blots (Fig. 11 in manuscript). All three functional domains of GRIM-12 are able to interfere with IFN/RA induced cell death, however the interface domain (ID) inhibits cell death the greatest (Fig. 12B in manuscript). In correlation with this result, TR enzyme activity is lowest in cells expressing the ID (Fig 12C in manuscript). This suggests that dimerization may be important for function of TR and that the ID region acts as a dominant negative mutant. In order to determine the role of GRIM-12 in other cell growth inhibition pathways, we treated mutant GRIM-12 expressing cells with etoposide, TNF- α and vincristine. No difference in growth inhibition between mutants and control cells was observed (Fig. 14 in manuscript). This suggests that GRIM-12 may specifically mediate IFN/RA induced death, or that other death activators induce alternative pathways to suppress cell growth. To study the effect of overexpression of GRIM-12 on cell growth, cells expressing wildtype GRIM-12 were also generated. These cells exhibit a slower growth rate, increased enzyme activity, and increased sensitivity to IFN/RA mediated PCD, compared to control cells (Fig 15 in manuscript). Taken together, we have shown that GRIM-12 expression and activity can influence cell growth and PCD induced by IFN/RA.

The ID peptide associates with full-length GRIM-12 in vitro: Since expression of the ID peptide was able to block cell death, presumably by competition with wildtype TR to form active dimers, we decided to see if ID could associate with GRIM-12 in vitro. Bacterially expressed ID and full-length GRIM-12 were expressed with different fusion tags (GST and His respectively) and purified on affinity columns. Purified products were incubated together and passed over either a glutathione sepharose column or a Ni-chelation sepharose column. Western blot analysis using a TR specific antibody was used to show that the ID domain could pull-down full-length GRIM-12 and vice-versa (Fig.13 in manuscript). The interaction was not mediated by the tags and the tags were unable to bind to a non-specific column. Therefore, ID may be able to associate with TR in vivo and inhibit enzyme activity, thus producing a dominant negative phenotype.

Cloning and sequence analysis of full length GRIM-1: Since we could not obtain a full-length cDNA clone of GRIM-1 from a library screen, we decided to use 5'RACE. After two rounds of 5'RACE, and subsequent ligations, a cDNA clone of 2.9 kb was obtained. This correlated with the smaller of the two mRNA species that hybridize with a GRIM-1 probe (previously reported as 2.6 kb and 2.8 kb, actually 2.9 kb and 3.1 kb respectively, upon further analysis). Sequence analysis revealed the presence of a 1.7 kb open reading frame (ORF) that encodes a polypeptide containing 577 amino acids. The predicted molecular weight is 64.8 kDa. Using various databases such as BLAST and Swissprot, we have confirmed that GRIM-1 is novel. However, the amino acid sequence has approximately 35% identity and 50% homology to *S. pombe* and *C. elegans* hypothetical proteins. The identity of these proteins is based on sequence that has been analyzed by programs such as Gene Finder. The existence of GRIM-1 homologues in other organisms indicates that the gene is evolutionarily conserved. Analysis of GRIM-1 with programs such as BLOCKS and MOTIF, we have identified several putative functional domains whose significance remains to be clarified. The GRIM-1 protein has two putative tyrosine phosphorylation sites that could play an important role in regulation and function. In addition, the carboxyl-terminal is serine and threonine rich suggesting the potential for serine/threonine phosphorylation. Amino-proximal to this domain is a region that is leucine and isoleucine rich. Several of these residues are six to eight amino acids apart indicating the possibility of forming a leucine zipper. Amino-proximal to this region is a putative zinc finger. Other domains of interest are two possible LXXLL motifs, which are found in co-activators of nuclear receptors (i.e. retinoid receptors), and an actin crosslinking domain that may target GRIM-1 to the cytoskeleton. These domains are only hypothetical and have yet to be proven relevant experimentally.

HeLa cells expressing antisense GRIM-1 are resistant to growth inhibition and cell death mediated by IFN- β /RA combination: In order to determine the role of GRIM-1 in cell growth control, we performed growth assays on the HeLa cell clone expressing the original antisense GRIM-1 episome. Expression of an antisense message was confirmed by Northern blots probed with GRIM-1 cDNA (data not shown). HeLa cells stably transfected with pTKO1 vector used as a control. In the presence non-cytotoxic concentrations of IFN- β and RA these cells are growth arrested (Fig.1). However, those cells expressing the antisense GRIM-1 episome continued to grow (Fig.1). Thus, in addition to having a role in PCD, GRIM-1 may suppress cell growth.

GRIM-1 is expressed in multiple tissues and cancer cell lines: Northern blots using a GRIM-1 cDNA probe on multiple human tissues revealed that the two previously identified transcripts are expressed in all tissues examined after stringent washing. Levels of GRIM-1 mRNA are higher in heart, skeletal muscle, kidney and liver (Fig.2). Interestingly, under less stringent conditions, GRIM-1 is able to hybridize with at least five additional transcripts in human heart and skeletal muscle and four other transcripts in kidney and liver (Fig.2). These blots are prepared with poly-A RNA and are normalized to nine different housekeeping genes. In addition, we probed the blot with a β -actin cDNA to confirm equal amounts of RNA (data not shown). These results suggest that GRIM-1 may be alternatively spliced or that a family of highly homologous GRIM-1-like proteins, encoded by different genes, may exist. These genes may be regulated in a tissue

specific manner. Northern blots were also performed on several cancer cell lines. Total RNA was prepared from cells that were either untreated or treated with IFN- β /RA combination for 48 hours. Blots were probed with a GRIM-1 cDNA and, after subsequent stripping, reprobed with GAPDH. In addition to MCF-7 and BT-20 breast cancer cells, GRIM-1 was inducible in cell lines from lung, colon and kidney (Fig.3). Thus the antiproliferative role of GRIM-1 may not be restricted to breast and cervical tissues.

Multiple tissue Northern blots from mouse were analyzed for the expression of GRIM-1. Unlike human tissues, we detected 2.2 kb and 2.4 kb GRIM-1 transcripts that expressed in most tissues (Fig.4). The levels of these transcripts expressed highest in heart, brain, liver, kidney, and testis. Very little expression was seen in skeletal muscle (Fig. 4). With the exception of skeletal muscle and brain, the expression patterns in human and mouse were similar (compare Figs. 1 and 4). Multiple GRIM-1 transcripts of various sizes were detected similar to human tissues (compare Figs. 2 and 4). We also used a mouse embryo blot to characterize the expression of GRIM-1 during murine development. Two transcripts with sizes of 2.2 kb and 4.5 kb were detected (Fig.5). The levels of expression for both transcripts increased from day 7 to day 15 and then decreased to almost undetectable levels at day 17, right before birth (Fig 4). This indicates that GRIM-1 may have a role during development.

GRIM-1 encodes three polypeptides in vitro by alternative initiation of translation:

The GRIM-1 cDNA was cloned into the pGEM7zf vector under the control of the T7 promoter. In vitro transcription and translation was performed using T7 polymerase and rabbit reticulate lysates. GRIM-1 cDNA encoded three polypeptides with the approximate molecular weights of 80 kDa, 73 kDa, and 45 kDa (Fig.6). Interestingly these proteins correspond to three translation start sites located within the same ORF. This was confirmed by cloning, via PCR, the three respective ORFs into pGEM7zf and repeating the in vitro analysis (Fig. 6). We have termed these three peptides as GRIM-1 α , β and γ . Initiation at multiple start sites can be accounted for by the lack of a good Kozak consensus sequence. The A in the -3 position has been shown to be important for translation fidelity. Furthermore, a change from the +4 G can also lead to 'leaky scanning' of the 40S ribosome subunit. Since the sequence surrounding the AUG codons of each isoform contains alterations in the consensus, it is conceivable that multiple peptides may be produced as a result. Interestingly, when the three ORFs were cloned and subsequently translated, a Kozak sequence was introduced immediately 5' of the AUG. This resulted in a shift towards translation initiation to the first AUG, further indication that the ribosomal endogenous binding sites are 'leaky' (Fig.6). One noteworthy observation was that the calculated MWs of these peptides were larger than their predicted MW (Fig.6). This may be due to phosphorylation.

Expression of GRIM-1 using bacterial expression systems: The ORFs for GRIM-1 α , β and γ were cloned into the pET32 inducible bacterial expression vector. Individual clones were transformed into the BL21 *E. coli* expression strain. Expression of GRIM-1 β and γ were unsuccessful while expression of GRIM-1 α is still pending. Possible reasons for failure of expression are that either the protein is toxic at high levels and is killing the bacteria before detectable protein is produced or that the codon usage for this strain of BL21 is inhibiting proper translation elongation. *E. coli* strains have different

tRNAs than eukaryotes for Leu, Ile, and Arg, all of which are abundant in GRIM-1. Therefore, we have taken three simultaneous approaches to solve this problem. First we will attempt expression in a codon-biased strain of BL21 that produces humanized tRNA to improve translation. Second we will attempt expression in a baculoviral system. And finally, we will attempt expression of a deletion mutant of GRIM-1 in bacteria. While the first two experiments are still ongoing, we have been successful at expressing a 25-kDa peptide in bacteria representing the carboxy-terminal end of GRIM-1 (Data not shown). This peptide is common to all three isoforms of GRIM-1. This protein has been purified by means of a poly-histidine tag on a Ni-chelation sepharose column. The tag has been removed and the pure protein has been sent for antibody production.

Appendices:

Figure Legends:

Figure 1: Effect of antisense GRIM-1 on cell growth suppression induced by IFN- β /RA combination in HeLa cells. Cells were grown in the presence of IFN- β (500U/mL) and RA (1 μ M) for indicated times. For each time point, cells were fixed and stained with sulforhodamine B and absorbance of bound dye was quantified with a plate reader. Each data point is the mean $\pm$ standard error (SE) of six replicates. Filled squares = HeLa cells expressing antisense GRIM-1; open circles = HeLa cells transfected with control vector.

Figure 2: Expression of GRIM-1 in different human tissues. Multiple tissue northern blot was probed with labeled GRIM-1 cDNA. PBL (peripheral blood leukocytes). Arrows indicate GRIM-1 specific transcripts.

Figure 3: Induction of GRIM-1 expression in various tumor cells by IFN- β /RA combination. In the upper panel, total RNA (40 μ g) from various tumor cells was northern blotted and probed with a labeled GRIM-1. In the lower panel, the same blot was stripped and re-probed with a labeled cDNA corresponding to the house keeping gene, GAPDH (glyceraldehyde phosphate dehydrogenase). MCF-7: ER⁺ breast carcinoma; BT-20: ER⁻ breast carcinoma; A375: Lung adenocarcinoma; ACHN: Renal carcinoma; Colo-320: Colon carcinoma. “-” and “+” signs indicate untreated and IFN/RA treated cells. Cells were treated for 48 hr, before RNA extraction.

Figure 4: Expression of GRIM-1 in different mouse tissues. A multiple tissue northern blot was probed with labeled GRIM-1 cDNA. Arrows indicate GRIM-1 specific transcripts.

Figure 5: Expression of GRIM-1 in embryonic murine tissues at various time points during development. A multiple tissue northern blot was probed with labeled GRIM-1 cDNA. Numbers above the lanes indicate the post- days of embryonic growth.

Figure 6: In vitro expression of GRIM-1 peptides. GRIM-1 cDNA or PCR products of ORFs were cloned into pGEM7zf vector under control of the T7 promoter and 1 μ g of plasmid was linearized, and transcription was performed using T7 RNA polymerase for 4

hrs. Transcribed RNA was analyzed by gel electrophoresis and equal amounts were diluted 1:10 before addition to rabbit reticulate lysates. Translation was carried out for 2 hrs in the presence of [³⁵S] methionine. Translation products were separated by SDS-PAGE and then dried, and flouorographed. Lane 1, control vector; lane 2, GRIM-1 γ ORF; lane 3, GRIM-1 β ORF; lane 4 GRIM-1 α ORF; lane 5, GRIM-1 full-length cDNA. Sequence is for ribosomal binding sites (Kozak consensus) of the, α , β , and γ proteins are shown. Conserved bases are underlined and the start codon is italicized.

Research Accomplishments 7/98 –7/99:

- Overexpression of GRIM-12 deletion mutants identifies the dimerization domain to be important for death activity.
- TR mediated PCD is specific to the IFN/RA cell death pathway.
- Overexpression of wildtype GRIM-1 increases cell mortality and sensitivity to IFN/RA induced PCD.
- Dimerization domain of GRIM-12 can associate with TR in vitro.
- Full length GRIM-1 is cloned and identified as a novel protein with various putative domains involved in protein-protein and protein-DNA interactions.
- Antisense knockout of GRIM-1 expression demonstrates it role in cell growth control induced by IFN/RA.
- GRIM-1 is expressed in multiple tissues in human and mouse in a tissue-specific and developmental manner, and is inducible by IFN/RA in several cancer cell lines.
- GRIM-1 cDNA can encode three peptides from the same ORF in vitro.
- GRIM-1 peptide was expressed in bacterial system and purified for antibody production.

Reportable outcomes:

Refereed Journal Articles:

Hofmann, E.R., Boyanapalli, M., Lindner, D.J., Weihua, X., Hassel, B.A., Jagus, R., Gutierrez, P.L., Kalvakolanu, D.V. (1998) Thioredoxin Reductase Mediates Cell Death Effects of the Combination of Beta Interferon and Retinoic Acid. *Mol Cell Biol* 18(11): 6493-504.

Abstracts/Presentations:

1. Lindner, D.J.*, **Hofmann, E.R.**, and Kalvakolanu, D.V. (1999) Overexpression of thioredoxin reductase (GRIM-12) enhances antiproliferative and apoptotic activity of IFN- β and tamoxifen in MCF-7 cells. (**Invited Speaker**). Second Annual Regional Cancer Center Consortium for Biological Therapy of Cancer, Rochester, NY

2. Lindner, D.J.*, **Hofmann, E.R.**, and Kalvakolanu, D.V. (1999) Overexpression of thioredoxin reductase (GRIM-12) enhances antiproliferative and apoptotic activity of IFN- β and tamoxifen in MCF-7 cells. (**Poster presentation**) annual meeting of the American Association for Cancer Research, Philadelphia, PA.
3. **Hofmann, E.R.***, Boyanapalli, M., Lindner, D.J., Weihua, X., Kalvakolanu, D.V. (1998) A Genetic Method Identifies Thioredoxin Reductase as a Mediator of Interferon and Retinoid Induced Cell Death. (**Oral presentation**) Second Joint Meeting of the ICS and the ISICR. Jerusalem, Israel.
4. **Hofmann, E.R.***, Boyanapalli, M., Lindner, D.J., Weihua, X., Kalvakolanu, D.V. (1998) Thioredoxin Reductase Mediates Growth Suppressive Effects of the Interferon Beta and Retinoic Acid Combination. (**Oral presentation**) 20th Annual Graduate Student Research Day. University of Maryland Baltimore County, Catonsville, Maryland.

(* presenting author)

Patents and licenses:

N/A

Degrees obtained:

N/A

Cell lines, tissue and serum repositories:

Various MCF-7 and BT-20 cell lines expressing wt TR and mutants as described in the manuscript: **Hofmann, E.R.**, Boyanapalli, M., Lindner, D.J., Weihua, X., Hassel, B.A., Jagus, R., Gutierrez, P.L., Kalvakolanu, D.V. (1998) Thioredoxin Reductase Mediates Cell Death Effects of the Combination of Beta Interferon and Retinoic Acid. *Mol Cell Biol* 18(11): 6493-504.

Informatics:

GRIM-12 sequences were deposited in GeneBank at the National Center for Biotechnology Information. The accession numbers are AF077367 for mRNA and AAC69621 for amino acid.

Funding applied for:

N/A

Employment applied for:

N/A




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

Thioredoxin Reductase Mediates Cell Death Effects of the Combination of Beta Interferon and Retinoic Acid

EDWARD R. HOFMAN,¹ MADANAMOHAN BOYANAPALLI,^{1,2} DANIEL J. LINDNER,^{1,2}
XIAO WEIHUA,^{1,2} BRET A. HASSEL,^{1,2} ROSEMARY JAGUS,³ PETER L. GUTIERREZ,²
AND DHANANJAYA V. KALVAKOLANU^{1,2,4,5*}

Department of Microbiology & Immunology,¹ Greenebaum Cancer Center,² Molecular and Cellular Biology Program,⁴ and Program in Oncology,⁵ School of Medicine, and Center of Marine Biotechnology,³ University of Maryland, Baltimore, Maryland 21201

Received 12 March 1998/Returned for modification 5 May 1998/Accepted 3 August 1998

Interferons (IFNs) and retinoids are potent biological response modifiers. By using JAK-STAT pathways, IFNs regulate the expression of genes involved in antiviral, antitumor, and immunomodulatory actions. Retinoids exert their cell growth-regulatory effects via nuclear receptors, which also function as transcription factors. Although these ligands act through distinct mechanisms, several studies have shown that the combination of IFNs and retinoids synergistically inhibits cell growth. We have previously reported that IFN- β -all-*trans*-retinoic acid (RA) combination is a more potent growth suppressor of human tumor xenografts *in vivo* than either agent alone. Furthermore, the IFN-RA combination causes cell death in several tumor cell lines *in vitro*. However, the molecular basis for these growth-suppressive actions is unknown. It has been suggested that certain gene products, which mediate the antiviral actions of IFNs, are also responsible for the antitumor actions of the IFN-RA combination. However, we did not find a correlation between their activities and cell death. Therefore, we have used an antisense knockout approach to directly identify the gene products that mediate cell death and have isolated several genes associated with retinoid-IFN-induced mortality (GRIM). In this investigation, we characterized one of the GRIM cDNAs, GRIM-12. Sequence analysis suggests that the GRIM-12 product is identical to human thioredoxin reductase (TR). TR is posttranscriptionally induced by the IFN-RA combination in human breast carcinoma cells. Overexpression of GRIM-12 causes a small amount of cell death and further enhances the susceptibility of cells to IFN-RA-induced death. Dominant negative inhibitors directed against TR inhibit its cell death-inducing functions. Interference with TR enzymatic activity led to growth promotion in the presence of the IFN-RA combination. Thus, these studies identify a novel function for TR in cell growth regulation.

Interferons (IFNs) are a group of multifunctional cytokines that stimulate antiviral, antitumor, and immunoregulatory activities (28). Upon binding to their receptors, IFNs activate a rapid signaling cascade wherein Janus tyrosine kinases (JAKs) induce the tyrosine phosphorylation of signal-transducing activators of transcription (STAT) proteins (10). IFN- α/β activate the phosphorylation of STAT-1 and STAT-2, which then associate with a 48-kDa DNA binding protein (p48) to form a multimeric transcriptional complex. This complex translocates to the nucleus, binds to the IFN-stimulated response element, and stimulates transcription. Similarly, IFN- γ induces the specific tyrosine phosphorylation of STAT-1 alone, which binds as a dimer to GAS (the IFN- γ -activated site) and activates transcription (10). These transcriptional complexes induce a number of unique as well as common cellular genes whose activities may be related to their diverse actions (58). Although a great deal is known about the antiviral actions of IFNs (58), the mechanisms responsible for their antitumor and immunoregulatory actions are unclear. *In vivo*, they up regulate the expression of tumor-specific antigens and natural killer cell and T-cell functions to mediate their antitumor effects (28). In addition to these mechanisms, IFNs directly activate growth-suppressive proteins such as pRb (32, 48) and down regulate c-Myc in certain lymphoid tumor cell lines (47). However, genetic evi-

dence for a tumor growth suppressor role exists only for certain members of the IFN gene-regulatory factor family. Gene mutations or dysregulation of IFN gene-regulatory factor 1 and IFN consensus sequence binding protein has been documented in human myeloid leukemias (25, 53, 64, 66). Since these molecules are IFN-regulated transcription factors, their activities are necessarily dependent on either the induction of growth-inhibitory gene products or the suppression of growth-promoting factors (64). However, the nature of these downstream factors is unknown. Some studies suggest that protein kinase R (PKR) and RNase L, which inhibit viral growth in IFN-treated cells (50, 59), also participate in growth suppression (3, 19). However, direct evidence for the role of these factors in the antitumor action of IFNs is lacking. Despite their strong therapeutic activity as single agents in a number of leukemias, IFNs are less effective in the therapy of solid tumors (18). To overcome such resistance, a number of therapeutic approaches have been developed. Among these, the combination of IFNs with retinoids is highly effective against several tumors (39). The molecular basis for the potentiated growth-suppressive action of the IFN-RA combination is unclear.

Retinoids are vitamin A derivatives that have strong influences on metabolism, cell growth and pattern formation (36). All-*trans*-retinoic acid (RA) and 9-*cis*-retinoic acid (9-cRA) are two major physiological retinoids that preferentially interact with specific nuclear receptors, which act as transcription factors (36). Ligand-activated heteromeric complexes of RA receptor, retinoid X receptor, and the associated coactivators up regulate the expression of genes (17) whose promoters

* Corresponding author. Mailing address: Department of Microbiology & Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201. Phone: (410) 328-1396. Fax: (410) 328-1397. E-mail: dkalvako@umaryland.edu.

contain retinoic acid response elements. Several isoforms and the corresponding subtypes of RA receptors and retinoid X receptors participate in a tissue and gene context-specific manner to induce gene expression (36). Retinoids suppress cell growth of certain primary skin dysplasias and tumor cell lines (26). However, the gene products that mediate these effects are unknown.

Clinical reports and studies with cultured tumor cells have shown that the IFN-RA combination is a more potent inhibitor of cell growth than is either agent alone (39). We have observed that the combination of human IFN- β with RA synergistically suppresses the growth of transplanted human breast and ovarian tumor xenografts in athymic nude mice (34). Here, we show that the IFN-RA combination causes cell death in vitro. To identify the genes responsible for cell death, we have used an antisense technical knockout approach (12). In this approach specific cell death-associated genes are identified by their ability to confer a growth advantage in the presence of death inducers when expressed in an antisense orientation. Using this method of cloning, we have identified several candidate genes that might participate in IFN-RA-activated cell death. In this study we have characterized one of these genes and identified it as human thioredoxin reductase (TR), an intracellular redox regulatory enzyme (16). We show that cellular TR levels are posttranscriptionally enhanced by the IFN-RA combination. Dominant negative mutants corresponding to the dimerization domain of TR interfere with death activation. Overexpression of one of the genes associated with retinoid-IFN-induced mortality (GRIM-12, whose product is identical to TR) enhances cellular susceptibility to IFN-RA-stimulated death. Thus, our studies attribute a novel function to TR in cell growth control.

MATERIALS AND METHODS

Reagents. Restriction and DNA-modifying enzymes (New England Biolabs), azelaic acid (AZ), dithiothreitol, phenylmethylsulfonyl fluoride, Triton X, imidazole, RA, sodium selenite (Sigma), G418 sulfate, isopropyl- β -D-thiogalactopyranoside (IPTG; Life Technologies); Ni-chelation-Sepharose (Novagen), glutathione-Sepharose (Pharmacia Biotech), nitrocellulose membranes, enhanced chemiluminescence (ECL) reagents, and horseradish peroxidase coupled to anti-rabbit antibodies (Amersham), human IFN- β_{ser} (Berlex Inc.), human IFN- α 2b (Hoffmann La Roche Inc.), human and murine IFN- γ (Boehringer Mannheim), murine IFN- β (Toray Industries), and hygromycin B (Boehringer Mannheim) were used in these studies. Monoclonal anti-eIF-2 α (57), anti-PKR (33) and RNase L (13) were described previously. Antiactin antibodies were from Santa Cruz Biotechnology. Fresh stocks of RA were prepared in ethanol and added to cultures under subdued light.

Cell culture. All estrogen-dependent cells were cultured in phenol-red free Eagle's minimal essential medium supplemented with 5% charcoal-stripped fetal bovine serum (CSFBS) and 10^{-11} M estradiol during treatment with IFN- β and RA. The cells were grown in phenol red-free medium 24 h before treatments were initiated. All other cell lines were cultured in media with phenol red but supplemented with 5% CSFBS prior to treatment with IFN- β and RA.

Cell growth assays. Cells (2,000 cells/well) were treated with various concentrations of IFN- β and RA in EMEM (Eagle's minimal essential medium)-5% CSFBS in 96-well plates. Growth was monitored for 5 to 7 days by a colorimetric assay, which monitors cell numbers (60). Each treatment group contained six replicates. The cells were fixed with 10% trichloroacetic acid (TCA) and were stained with 0.4% sulforhodamine B (Sigma) in 1% acetic acid for 1 h at the end of the experiment. After the cells were washed, the bound dye was eluted from the cells with 100 μ l of Tris-HCl (pH 10.5) and the absorbance was measured at 570 nm. One control plate was fixed with TCA 8 h after plating to determine the absorbance representing the starting cell number. The absorbance obtained with this plate was considered to represent 0% growth. The absorbance obtained with untreated cells was taken as 100% growth. When expressed as a percentage of the value for untreated controls, an increase in cell number falls on the positive scale and a decrease in cell number (death) appears on the negative scale. This method quantitates cell growth with an accuracy comparable to that of Coulter counting. To determine the cell cycle distribution, cells collected after various treatments were fixed and stained with propidium iodide as described previously (62). The samples were analyzed by flow cytometry (Becton-Dickinson).

Construction of the antisense expression library. Total RNA from the BT-20 breast tumor cell line, treated with IFN- β (500 U/ml) plus RA (1 μ M) for 0, 2,

4, 8, 16, 36, 48, and 72 h, was prepared with RNazol B reagent (Tel-Test). These RNAs were pooled, and total poly(A)⁺ RNA was isolated with the polyAtract system (Promega). cDNA libraries were constructed with commercially available kits (Stratagene) as recommended by the manufacturer. A 10- μ g portion of mRNA was used for preparing the cDNA library, with an oligo(dT) primer, in the presence of a deoxynucleoside triphosphate mixture that contained 5-methyl-dCTP. After second-strand synthesis, ends and gaps were filled with *Pfu* thermal DNA polymerase to ensure that the cDNA was blunt ended. The cDNAs were ligated to a synthetic double-stranded bifunctional linker, 5'-GCTTGGATCCA AGC-3'. When attached to the 3' end of the cDNA, this linker generated a *Hind*III site. Ligation at the 5' end created a *Bam*HI site (37). The library was then digested with *Hind*III and *Bam*HI, purified on a Sepharose 6B column, and inserted into an episomal vector, pTKO1, which carried markers for selection in eukaryotic (hygromycin resistance) and bacterial (ampicillin resistance) cells (12). When cloned into the *Bgl*II and *Hind*III sites of the pTKO1 episomal vector, the cDNA replaced the existing chloramphenicol acetyltransferase gene and the cDNA was expressed in an antisense orientation. The library was then transformed into *Escherichia coli* DH10B, which takes up large plasmids with methylated DNA, and was plated on several 150-mm-diameter plates. The bacteria were scraped from the plates, and plasmid DNA was extracted and purified on CsCl gradients. This unamplified library was used for transfection. After electroporation of the library (40 μ g) into HeLa cells (10⁷), the cells were distributed among several 150-mm plates. Drug selection was initiated with hygromycin B (200 μ g/ml), human IFN- β (3,000 U/ml), and RA (5 μ M) and continued for 4 weeks. Parallel plates transfected with pTKO1 were selected similarly. All these cells died after 10 to 12 days of selection. The medium was changed and fresh drugs were added daily for the first week and then every other day. At the end of 4 weeks of selection, the surviving colonies were pooled and expanded in the presence of hygromycin B (200 μ g/ml), and Hirt DNA extracts were prepared (22). DNA was digested with *Dpn*I and electroporated into *E. coli* DH10B. The resultant colonies were screened by PCR with plasmid-specific primers to detect the presence of inserts. Inserts were sequenced to identify the gene products.

Each individual episome was tested for cell protection against IFN-RA-induced death in several breast carcinoma cell lines. Individual episomes (20 μ g) mixed with 30 μ g of salmon sperm DNA were electroporated into cells (10⁶) in Dulbecco's minimal essential medium with 10% FBS and 5 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES). The electroporation conditions were 250 V, 900 μ F, and 13 Ω in a BTX electroporator. Triple selection with IFN- β (500 U/ml), RA (1 μ M), and hygromycin B (100 μ g/ml) was initiated after 24 h. The cells were selected for 20 days with three drugs. After that, they were grown in medium containing hygromycin B alone. All cells that received only pTKO1 died by 10 to 12 days of triple selection.

Construction of dominant negative mutants. Dominant negative mutants were constructed by PCR with the following primers. FAD (flavin adenine dinucleotide binding active domain) was generated with 5'-CCAAGCTTATGAACGG CCCTGAAGATC as the forward primer and 5'-CCGAATTCTCATAAGCAT TCTCATAGACGAC-3' as the reverse primer. NBD (NADPH binding domain) was prepared with 5'-CCAAGCTTATGCAATTTATTGGTCTCTACAG-3' as the forward primer and 5'-CCGAATTCTCATGTCTTATAAAGCTTGATGC C-3' as the reverse primer. The ID (interface domain) was generated by using 5'-CCAAGCTTATGGTGCCTTACATCTATGCC-3' as the forward primer and 5'-CCGAATTCTCAGCAGCCAGCCTGGAG-3' as the reverse primer. The respective start and stop codons are shown in boldface. PCR products were digested and cloned into the pCXN2 mammalian expression vector, in which the chicken actin promoter regulated the expression of mutants. It also carried a neomycin resistance marker for selection in mammalian cells. Stable transfectants were generated by electroporation of cells with indicated plasmids and selection with G418 (500 μ g/ml). After 3 weeks of selection, surviving clones were expanded for further studies. Individual mutants were designated FAD, NBD, or ID. Expression of mutants was monitored by Northern blot analysis.

Overexpression of GRIM-12. To study the effects of overexpression on cell growth, the GRIM-12 open reading frame (ORF), without the untranslated region (UTR) sequences, was subcloned into eukaryotic expression vector pCXN2. In addition, a Kozak consensus sequence was placed upstream of ATG codon for proper translation. The insert was checked for expression by in vitro transcription and translation before being cloned into pCXN2 (data not presented). Because of the removal of the UTRs, the transfected gene encodes a ~1.4-kb mRNA which can be readily distinguished from the endogenous one by Northern blot analysis. The cells were stably transfected with comparable concentrations of pCXN2 and GRIM-12 expression vector separately. Multiple plates were included in the experiment and selected for G418 resistance. At the end of 4 weeks of selection, one set of plates was stained with Giemsa to count the number of colonies formed. In each case, drug-resistant clones growing in second set of parallel plates were pooled and used for Northern blot, enzyme, and growth analyses.

Northern blot analysis. Total RNA (20 μ g) was separated on 1% formaldehyde-agarose gels, transferred to a nylon membrane, and probed with the ³²P-labeled PCR product of GRIM-12 cDNA. Prehybridization, hybridization, and washing was carried out under stringent conditions (27).

Western blot analysis. Total protein was extracted by freeze-thaw method after various treatments. Total protein (10 μ g) was separated on a 10% acryl-

amide gel and transferred to a polyvinylidene difluoride membrane (NEN). The membranes were incubated with a primary antibody raised against the peptide VVG FHVLPNAGEVTQGF AA, derived from the native enzyme (16). After stringent washing, the membranes were incubated with anti-rabbit immunoglobulin G (IgG) antibody conjugated to horseradish peroxidase and developed with ECL reagents.

In vitro transcription and translation. GRIM-12 was subcloned into pBlue-script KS vector (Stratagene) under the control of the T7 promoter. Plasmid DNA (1 µg) was linearized with *Hind*III, and in vitro transcription was performed with the T7 RNA polymerase (Promega). The resultant RNA was programmed into nuclease-treated rabbit reticulocyte lysates (Promega) in the presence of [³⁵S]methionine. Translation products were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10% polyacrylamide), dried, and fluorographed.

Bacterial expression. pET-32B (Novagen) and pGEX-2TK (Pharmacia Biotech) were used as cloning vectors. The GRIM-12 ORF was PCR amplified from the pTKO1-GRIM-12 cDNA clone with the forward primer 5'-CCAAGCTTA TGAACGGCCCTGAAGATC-3' and the reverse primer 5'-CCGAATTCTCA GCAGCCAGCCTGGAG-3' (start and stop codons in boldface). These primers contained *Hind*III and *Eco*RI sites, respectively, for directional cloning. PCR was carried out for 10 cycles. The PCR product was treated with T4 DNA polymerase and digested with *Hind*III. It was subcloned into pET-32B at the *Hind*III and *Xho*I sites (the sites were blunt ended). ID was PCR amplified from pTKO1-GRIM-12 cDNA clone DNA with the forward primer 5'-CCAAGCTTATGGT GCCCTACATCTATGCC 3' and the reverse primer 5'-CCGAATTCTCAGCA GCCAGCCTGGAG 3'. These oligonucleotides contained *Bam*HI and *Eco*RI restriction sites, respectively, for subcloning the amplified inserts. The PCR product (535 bp) was digested with *Eco*RI and *Bam*HI and subcloned into pGEX-2TK.

pET-32B-GRIM-12 and pGEX-2TK-ID were transformed into *E. coli* BL21DE3, and transformants were grown in 2YT medium (Life Technologies Inc.). A 2-liter culture was induced with IPTG (0.1 mM) at mid-log phase for 4 h at 37°C. The cells were harvested, washed with 200 ml of buffer (20 mM Tris-HCl [pH 7.9], 500 mM NaCl, 1 mM MgCl₂, 1 mM CaCl₂, 0.01% Triton X, 5 mM dithiothreitol) and suspended in 20 ml of buffer. They were sonicated, and the clarified supernatants were passed through Ni-chelation-Sepharose or glutathione-Sepharose 4B depending on the fusion tag as recommended by the manufacturer. After elution, the proteins were separated by SDS-PAGE (10% polyacrylamide) and subjected to silver staining.

Protein interaction studies. Purified GRIM-12 and ID proteins were mixed and incubated for 15 min at 25°C and then for 15 min at 4°C in enzyme assay buffer. After incubation, the samples were passed through Ni-chelation-Sepharose or glutathione-Sepharose 4B columns, washed extensively with HEPES (pH 7.6) containing 50 mM NaCl, and eluted. The proteins were separated by SDS-PAGE (10% polyacrylamide). The gels were electroblotted onto a polyvinylidene difluoride membrane, probed with TR-specific antibody, and developed with ECL reagents to visualize the bands. Western blotting was chosen to discern any residual nonspecific interaction through the tags.

Enzymatic assay. TR activity was determined as described previously (23). Cell extracts were prepared by freeze-thaw lysis after IFN-RA treatment. A 20-µg portion of extract was incubated with insulin, NADPH, and thioredoxin (Trx) in 0.2 M HEPES (pH 7.6) for 20 min at 37°C. The reactions were stopped with 6 M guanidinium hydrochloride–0.4 mg of dithiois(2-nitrobenzoic acid) per ml in 0.2 M Tris (pH 8.0). The absorbance at 412 nm was measured. In each case, a corresponding control without Trx was used to determine the basal level of TR activity (due to endogenous Trx and NADPH). Absorbance values obtained from these controls were subtracted from those obtained with the reaction mixtures that contained Trx and NADPH. A control reaction without cell extracts but with all the reaction components was also used. Triplicate samples were measured for enzymatic activity. Pure TR was used as a positive control.

PKR and RNase L assays. PKR activity was measured by eukaryotic protein synthesis initiation factor (eIF-2α) phosphorylation (51). Phosphorylation of eIF-2α was monitored by vertical slab isoelectric focusing followed by Western blotting with eIF-2α-specific antibodies. Cell lysates were also analyzed for the presence of PKR, eIF-2α, and actin by Western blotting with specific antibodies. RNase L activity was monitored by cross-linking equal amounts of cell extracts with ³²P-labeled 2-5A (42) followed by SDS-PAGE (10% polyacrylamide) and autoradiography. Levels of RNase L protein were measured with a monoclonal antibody against human RNase L. The activity of these enzymes in tumor samples was determined as follows. Athymic nude mice bearing palpable human tumor xenografts (5 mm in diameter) were treated with the indicated agents for 8 weeks as described previously (34). Tumors from each treatment group were harvested and snap frozen in liquid nitrogen, and tumor protein extracts (50 µg) were assayed for enzymatic activity.

Nucleotide sequence accession number. The GenBank accession number for the sequence of GRIM-12 is AF077367.

RESULTS

The IFN-α, IFN-β, and RA combination synergistically induces cell death in human breast carcinoma cells. We have




FIG. 1. Cells were grown in the presence of various doses of IFNs and RA (1 µM) for 7 days. At the end of the experiment, the cells were fixed and stained with sulforhodamine B as described in Materials and Methods. The absorbance at 570 nm of bound dye was quantified and expressed as a percentage of untreated controls. Each datum point is the mean $\pm$ standard error (SE) of six replicates. Symbols: $\circ$, IFN- α ; ∇ , RA plus IFN- α ; $\blacktriangledown$, IFN- β ; $\blacksquare$, RA plus IFN- β ; $\diamond$, IFN- γ ; $\blacklozenge$, RA plus IFN- γ ; $\bullet$, RA. Human MCF-7 and BT-20 and murine RB1 breast carcinoma cells were treated with human and murine IFNs, respectively. Absorbance values for 0 and 100% growth in this assay, respectively, are as follows: MCF-7, 0.185 and 1.75; BT-20, 0.201 and 2.03; and RB1, 0.172 and 1.59. Values on the negative scale indicate death of initially plated cells.

previously shown that the human IFN- β -RA combination was a stronger inhibitor of human tumor growth in athymic nude mice than either agent alone (34). Since the IFN- β used in that study was highly species specific and these mice lacked cytotoxic T cells, we hypothesized that growth suppression was largely due to a direct effect of the human IFN- β -RA combination on the tumor cells rather than an activated host immune system. To directly demonstrate that the IFN-RA combination was tumoricidal in vitro, we treated several breast carcinoma cell lines with various IFNs alone or in combination with RA and, after 1 week, measured cell growth with sulforhodamine B (60). Increasing doses of IFN- α or IFN- β alone did not cause significant growth inhibition in MCF-7 (an estrogen-responsive breast carcinoma cell line) in vitro (Fig. 1A). Similarly, RA (1 µM) alone did not significantly inhibit growth. Combination of various doses of IFN- α or IFN- β with RA caused dose-dependent growth inhibition. When combined with RA, IFN- α or IFN- β caused cell death at low doses (150 to 200 U/ml). Although both IFNs in association with RA were cytotoxic in vitro, in several experiments IFN- β was consistently a more potent inducer of cell death than was IFN- α . To determine whether cell death could be observed in estrogen-independent cells, we examined the effects of the IFN-RA combination in BT-20 cells (Fig. 1B). RA alone failed to inhibit BT-20 cell growth. Unlike MCF-7, BT-20 cell growth was inhibited by IFN- β . However, the combination of RA (1 µM) with IFN- β (100 U/ml) caused cell death. Similarly, murine IFN- β -RA induced death in RB1, a cell line derived from a polyomavirus-transformed murine breast tumor (Fig. 1C). Although the data in the figure depict partial cell death, all the cells were killed by the combination after 9 days in various experiments (data not




FIG. 2. MCF-7 cells were treated with RA (1 μ M) or IFN- β (500 U/ml) or the combination for 5 days. The cells were fixed and stained with propidium iodide after RNase A treatment. Fluorescence-activated cell sorter and cell cycle analyses were performed. Dead cells are indicated by a solid arrow.

shown; see Fig. 4). To examine whether RA also enhanced the cell growth-inhibitory actions of IFN- γ , similar growth assays were performed. IFN- γ alone did not inhibit growth, but cotreatment with RA enhanced its effect (Fig. 1D to F). Notably, the IFN- γ -RA combination did not cause cell death even at higher doses (500 U/ml). Thus, type I IFNs, when combined with RA, cause cytotoxicity in several tumor cell lines.

Microscopic examination of cells demonstrated a dose-dependent cytotoxic effect. Scanning electron microscopic analyses revealed a phenotype consistent with programmed cell death (data not presented). However, we did not observe classical internucleosomal fragmentation of genome in terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays (data not presented). To determine whether there was an arrest of cells in a given phase of cell cycle during induction of death, the cells were treated with various agents for 5 days, stained with propidium iodide, and analyzed by fluorescence-activated cell sorting. Untreated cells exhibited a normal cell cycle profile (Fig. 2A). Neither IFN- β nor RA caused cell cycle arrest, consistent with the cell growth assays. Interestingly, the IFN- β -RA combination also did not cause cell cycle arrest yet readily induced cell death (Fig. 2D). Although in qualitative terms the IFN-RA-treated cells appear to show some accumulation in G₂/M, quantitative data from several experiments did not reveal a significant difference from other controls (data not presented). The hypodiploidy seen in Fig. 2D may represent the cell corpses containing randomly digested subnuclear components. Thus, cell death occurred independently of growth arrest.

IFN-RA-mediated cell death does not involve known IFN-stimulated gene products. We next examined whether induction of cell death was due to an enhanced activity or expression of IFN-stimulated gene products known to cause growth arrest and apoptosis. Two gene products, PKR and RNase L, have been shown to cause growth inhibition in some cell types (3, 19). The cells were treated with various agents for 5 days, and the enzymatic activities of these proteins were analyzed. No increase in 2',5'-oligoadenylate synthetase activity was noted after any of the treatments (data not shown). A downstream enzyme, RNase L, cleaves cellular RNAs after binding to 2',5'-oligoadenylates (59). There was no change in the levels of RNase L or the 2',5'-binding activity, an indirect measure of

active enzyme (Fig. 3A and B). RNase L activity was measured in MCF-7 cells treated *in vitro* (lanes C) and also in tumor xenografts (lanes T) that regressed *in vivo* after IFN-RA therapy. In all cases, RNase L activity was not significantly different from that of untreated controls (lanes N). We also did not detect cleavage of rRNA, a characteristic of RNase L activation, in these cells (data not shown).

Another IFN-induced enzyme, PKR, phosphorylates eIF-2 α , leading to a cessation of polypeptide synthesis and cell growth arrest (50). There was no change in the levels of PKR and eIF-2 α or the enzymatic activity of PKR in MCF-7 cells (Fig. 3C, D, and F). Phosphorylation of eIF-2 α occurred in confluent NIH 3T3 cells but not in subconfluent ones (3, 50). However, phosphorylation of eIF-2 α in MCF-7 cells treated either with IFN- β , RA, or the combination was not different from that of untreated cells (Fig. 3F, lanes 3 to 6). Similarly, no increase in the intratumoral PKR activity was observed following any treatment in MCF-7 tumors (data not shown). In addition, we did not detect an increase in p53 tumor suppressor or BAX (a promoter of cell death) or a decrease in Bcl2 (an inhibitor of death) under these conditions (data not shown).

Genetic approach to isolation of cell death genes. Because no correlation could be found between the expression of known growth-regulatory genes and IFN-RA-induced cell death, we sought to identify the death-associated genes by using an antisense knockout approach (12). In principle, a death-associated gene can be isolated by antisense inactivation of the gene. In this method, cells are transfected with an antisense cDNA library derived from tumor cells cloned in an episomal expression vector. If this library contains death-mediating gene products, the corresponding antisense RNA will inhibit the expres-




FIG. 3. Activation of IFN-stimulated growth-inhibitory gene products does not occur during IFN-RA-induced cell death. (A) Binding of ³²P-2',5'-oligoadenylate to RNase L. (B) Western blot analysis of RNase L. Labels above the arrows: N, no treatment; I, IFN- β ; R, RA; I+R, IFN- β plus RA. Labels below the arrows: C, cultured MCF-7; T, MCF-7 tumor xenograft in athymic nude mice. The following doses were used: *in vitro*, RA (1 μ M) and IFN- β (500 U/ml) for 5 days; *in vivo*, RA (300 μ g, oral) and IFN- β (10⁶ U, subcutaneous) every day for 40 days. Cell or tumor extracts (70 μ g) were assayed for various proteins. (C to E) Western blot analyses of MCF-7 lysates (50 μ g) with specific antibodies: anti-PKR (C), anti-eIF-2 α (D), and anti-actin (E). (F) PKR activity as measured by phosphorylation of eIF-2 α . Lanes 1 and 2 represent PKR activity in the untreated and hemin- and double-stranded dsRNA-treated reticulocyte lysates (50 μ g), respectively. Lanes 3 to 6 show PKR activity in MCF-7 lysates (50 μ g) after treatment with various agents *in vitro*. After vertical slab gel isoelectric focusing, the gels were Western blotted and probed with anti-eIF-2 α -specific antibodies. The positions of phosphorylated and unphosphorylated eIF-2 α are indicated by solid and open arrowheads, respectively. The labels above panels C to F are as explained above for panel A.




FIG. 4. Protection of MCF-7 cells by antisense GRIM-12 episome. The cells were electroporated with the indicated episomes (20 μ g) and selected for 4 weeks with IFN- β (500 U/ml), RA (1 μ M), and hygromycin B (100 μ g/ml). Surviving cells were fixed with TCA (10%) and stained with Giemsa.

sion of that endogenous gene. Consequently, only cell clones that express the death-related antisense mRNA will survive in the presence of the death inducer. Hirt DNA extracts from the surviving cell clones can be isolated and transformed into *E. coli* to rescue the inserts. The rescued episomes are retransfected individually into the breast tumor cells to identify the death-related products and eliminate false-positives isolated in the first round of transfection.

To isolate the death-associated genes, we prepared antisense cDNA libraries cloned in the episomal vector, pTKO1 (see Materials and Methods). An IFN-stimulated gene promoter drives the expression of antisense RNAs in this vector. This library (40 μ g) was electroporated into HeLa cells (~50% transfection efficiency) and selected for resistance to hygromycin B, human IFN- β , and RA as described in Materials and Methods. Hirt DNA extracts were prepared from surviving clones, digested with *DpnI* (to inactivate unreplicated input DNA), and transformed into *E. coli* DH10B by electroporation. A total of 24 individual episomes were rescued in the first round. Each purified episome was then individually transfected into MCF-7 and BT-20 breast carcinoma cell lines and examined for cell protection against IFN-RA-induced death. At the end of two rounds of screening, 14 episomes consistently conferred growth advantage to cells in the presence of IFN-RA (500 U/ml plus 1 μ M). Partial sequence analyses revealed that several of these were novel genes (data not shown). We have named them GRIM (genes associated with retinoid-IFN-induced mortality). We chose one of these, GRIM-12, for further characterization, mainly because it contained the largest insert. GRIM-12 clearly protected MCF-7 cells against IFN-RA-induced death (Fig. 4). No surviving colonies were seen in the control plate transfected with pTKO1 vector alone. Thus, transfection of the GRIM-12 (in antisense orientation) episome conferred strong protection against IFN-RA-induced death.

Identification of GRIM-12 as human TR. The GRIM-12 episome was completely sequenced on both strands. An ORF capable of encoding a 495-amino-acid polypeptide, and long 3' and 5' UTRs were present in this cDNA. The 5' UTR in the

clone we isolated is incomplete. The 3' UTR is 1,896 bases long. The predicted molecular mass of the protein is 54.4 kDa. Figure 5 shows the deduced amino acid sequence of this cDNA. Sequence analysis revealed that this cDNA was identical to that of human TR (16), except for an arginine in place of serine at 156, an asparagine in place of glycine at 215, and an arginine in place of serine at 491. The active center of the enzyme appears to be formed by the cysteine residues at 57 and 62. Homology searches revealed that in addition to TR, it was identical to a protein described as "KM-102 bone marrow-derived reductase-like factor" (GenBank accession no. D88687) between residues 53 and 549 (38). However, the KM-102 reductase has an additional 52 amino acids that is unique to it. The deduced protein sequence also exhibited a close homology to a predicted glutathione reductase gene from *Caenorhabditis elegans*.

To examine whether the GRIM-12 cDNA contained an intact ORF, the insert was cloned into pBluescript under the control of T7 promoter. The cloned insert was transcribed and translated in vitro with rabbit reticulocyte lysates. GRIM-12 cDNA encoded a protein that migrates as a 58-kDa species on SDS-PAGE (10% polyacrylamide) (Fig. 6A). The ORF was also placed downstream of a histidine tag in pET32B vector and expressed in *E. coli*. The fusion protein was purified on Ni-chelation columns. A 78-kDa fusion protein was expressed (Fig. 6B). This protein contained 20 kDa of tag-derived sequences. Removal of tag sequences yielded a 58-kDa protein (data not shown). Thus, in both eukaryotic and bacterial expression systems, it encodes a polypeptide of 58 kDa, which was higher than the predicted 54.7 kDa. This difference could be due to posttranslational modifications. Indeed, sequence analyses suggested several phosphorylation sites. However, the contributions of these sites to the enzyme activity remain to be determined. Bacterially expressed fusion protein was analyzed in Western blots with rabbit polyclonal antibodies specific for human TR. These antibodies readily recognized the fusion protein but not the tag (Fig. 6B). Thus, GRIM-12 encoded TR.

Effect of the IFN-RA combination on the expression of GRIM-12. To study the effect of the IFN-RA combination on GRIM-12, we first examined whether its mRNA levels were inducible. Treatment of MCF-7 and BT-20 cells with the IFN-RA combination did not induce the mRNA significantly, although a marginal increase could be seen at 48 or 72 h (Fig. 7). Reprobing of these blots with a glyceraldehyde 3-phosphate dehydrogenase probe confirmed the presence of comparable amounts of RNA in all the lanes (data not shown). Thus, the IFN-RA combination does not regulate the transcription of GRIM-12.

To examine whether the IFN-RA combination enhanced the expression of GRIM-12 protein, Western blot analysis was performed. The IFN-RA combination induced GRIM-12 protein in a time-dependent manner. There was no detectable induction until 8 h posttreatment. Between 8 and 72 h, the TR

MNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGGKVMVLDVFTPTPLGTRWGLGGTCVNVGCI PKKLMHQAALLG
QALQDSRNYGWKEETVKHWDWRMIEAVQNHIGSLNWGYRVALREKKVYENAYGQFIGPHRIKATNNKGKEKIYSA
ERFLIATGERPRYLGPIDGKEYCISDDLFSLPYCPGKTLVVGASYVALECAAGFLAGIGLNVTVMVRISILLRGFDQD
MANKIGEHEEHGIKFIRQFVPIKVEQIEAGTPGRLRVVQAQSTNSEIIEGEYNTVMLAIGRDACTRKIGLETVGVK
INEKTGKIPVTDEEQTNVPYIYAIGDILEDKVELTPVAIQAGRLLAQRLYAGSTVKCDYENVPVTFPTPLEYGACGL
SEEKAVEKFEENIEVYHSYFWPLEWTIPSRDNNKYAKIICNTKDNERVVGFGHVLGPNAGEVTQGFAAALCKGLTK
KQLDSTIGHVPVCAEVFTTSLVTKRSGARILQAGC

FIG. 5. Amino acid sequence of GRIM-12. Cysteine residues of the active site (underlined) are shown in boldface.




FIG. 6. Identification of GRIM-12 as human TR. (A) GRIM-12 cDNA cloned in pBluescript (pBS) vector was transcribed and translated in vitro by using rabbit reticulocyte lysate. The protein encoded by GRIM-12 is indicated by an arrow. (B) Expression of GRIM-12 in bacteria. Bacterial lysates were purified on a Ni-chelation-Sepharose column before SDS-PAGE and silver staining. (C) Western blot analysis of the protein samples shown in panel B, using a human TR-specific antibody.

protein level increased progressively (Fig. 8). We next determined whether an increase in the TR protein level correlated with an increase in enzymatic activity. Insulin reduction assays were performed to measure TR activity by using cell extracts from IFN-RA-treated cells. Indeed, the enzymatic activity of TR increased progressively with the length of IFN-RA exposure of cells (Fig. 9). The decrease in the enzymatic activity at 92 h posttreatment may be due to extensive cell death at that particular point.

Antisense inhibition of TR expression by GRIM-12. Since the above experiments indicated that an increase in the TR activity was responsible for death, we determined whether cell survival was due to a reduction of TR expression in the cells expressing the GRIM-12 episome. Because original antisense rescue was performed in HeLa cells, we used two stably selected pools of HeLa cells, one that expressed the pTKO1 vector alone and one that expressed the GRIM-12 antisense episome. Northern blot analysis revealed a strong expression of antisense mRNA only in the GRIM-12-transfected cells (Fig. 10A). To determine if antisense GRIM-12 caused a reduction in the level of TR protein, equal amounts of total cell lysates from these cells were subjected to Western blot analysis. Indeed, antisense expression of GRIM-12 mRNA accompanied a strong reduction in the level of TR protein (Fig. 10B). Using the same extracts, we also determined the enzyme activity. Cells expressing antisense GRIM-12 had a sevenfold lower TR activity compared those from the control cells (Fig. 10C). These data indicate that antisense expression of GRIM-12 in long-term culture can repress TR expression.

Overexpression of GRIM-12 mutants inhibits IFN-RA-induced cell death. Since GRIM-12 (TR) was isolated as an activator of IFN-RA-stimulated cell death, we next examined whether overexpression of specific subdomains of TR in the cells would also ablate the death induction by the IFN-RA combination. Based on its relationships to other members of the glutathione reductase-TR family, a modular structure of GRIM-12 was predicted (16). An N-terminal FAD binding domain (FAD domain or active domain) and a central NADPH binding domain (NBD) and a C-terminal interface domain (ID) are the major functional modules of this enzyme (Fig. 11A). The FAD domain contains the cysteine residues essential for the reduction of its substrate, Trx. The NBD binds NADPH, an essential cofactor for redox enzymes. The inter-




FIG. 7. Northern blot analysis of GRIM-12 with RNA (20 µg) derived from MCF-7 and BT-20 cells after treatment with the IFN-β (500 U/ml)-RA (1 µM) combination.

face domain is crucial for the generation of functional enzyme via dimerization.

To determine whether these domains acted as dominant inhibitors of endogenous GRIM-12 (TR), we created deletion mutants that contained only one domain by using region-specific oligonucleotides and PCR. These inserts were subcloned into an eukaryotic expression vector, pCXN2, which also carried a neomycin resistance gene for selection in mammalian cells. Recombinant vectors were then transfected into MCF-7 and BT-20 cells, and stable cell lines were established. Expression of the GRIM-12 mutants was ascertained by Northern blot analysis (Fig. 11B). Comparable amounts of mutant domains were present in the cell lines. As anticipated, expression of GRIM-12 mutants was not seen in cells that were transfected with vector alone. No differences in the growth rates of stable cell lines expressing various mutants were noted (data not presented).

To test the effects of IFN, RA, and their combination, growth assays were performed with cell lines that expressed various domains of GRIM-12. Treatment with either IFN-β (500 U/ml) or RA (1 µM) alone did not cause significant growth inhibition in any cell line (Fig. 12A). These observations were consistent with the sensitivities of the parental cell line (Fig. 1). However, treatment with the IFN-RA combination induced cell death in untransfected cells and those that were transfected with vector alone. Expression of the FAD domain did not significantly inhibit the cell growth-suppressive effect of IFN-RA. The NADPH binding domain conferred slight protection against IFN-RA-induced cell death. However, the ID provided the strongest protection compared to other domains (Fig. 12B). Remarkably, the IFN-RA combination could inhibit ~60% of cell growth even when the ID was overexpressed. This was not a clonal effect, because similar data were obtained for a pooled population of 100 clones (data not presented). Similar results were obtained with BT-20 cells (data not shown). These data confirmed the role of GRIM-12 as a mediator of cell death in response to IFN-RA treatment.

We next examined whether ablation of IFN-RA-suppressed cell growth was due to a decrease in the enzymatic activity of TR in cells expressing the mutants. Insulin reduction assays




FIG. 8. Western blot analysis of cell extracts (70 µg) prepared after IFN-β (500 U/ml)-RA (1 µM) treatment as in Fig. 7. The blots were probed with TR-specific antibody.




FIG. 9. TR activity in IFN-RA-stimulated MCF-7 cell extracts. The cells were treated as described in the legend to Fig. 8. TR activity was determined with 20 μ g of cell extract from each sample. Each bar represents the mean absorbance $\pm$ SE of triplicate measurements.

were performed to detect these differences. Cells that expressed vector alone had the highest enzymatic activity (Fig. 12C). Cells expressing the FAD domain had a marginal loss of enzymatic activity. Cells with the NBD had intermediate inhibition of TR activity. Expression of ID caused the greatest reduction in enzymatic activity. Thus, ablation of enzymatic activity correlated well with loss of growth suppression by the IFN-RA combination (Fig. 12C).

Since IFN-RA-induced growth inhibition occurred in the cells expressing the ID mutant, it is possible that the mutant acts as an inefficient inhibitor due to a nonnative structure. Therefore, we examined the effect of AZ, a known chemical inhibitor of TR (52), on IFN-RA-induced cell death. As expected, IFN-RA caused cell death in MCF-7 cells. Although AZ itself was slightly inhibitory (7%) under the growth conditions used, it clearly abrogated IFN-RA-stimulated death in MCF-7 cells (Fig. 12D). Interestingly, IFN-RA caused significant growth inhibition (70%) even in the presence of AZ. Thus, genetic and chemical inhibition of TR ablates IFN-RA-induced cell death. Importantly, IFN-RA-induced growth-inhibitory actions continue to operate under both these conditions.

The ID associates with full-length TR in vitro. The above results suggested that the dominant negative effect of ID was probably due to its interaction with endogenous TR. To directly test whether ID interacted with the full-length protein, we expressed both these proteins separately in *E. coli*. Full-length GRIM-12 and ID were expressed as His-tag fusion and glutathione *S*-transferase (GST) fusion proteins, respectively. Purified proteins (Fig. 13A and B) were tested for interaction with each other on different matrices (Fig. 13C). These proteins were incubated in HEPES (pH 7.6) and then passed over either Ni-chelation-Sepharose (Fig. 13C, lanes 1 to 4) or glutathione-Sepharose (lanes 6 to 9). The Sepharose-bound material was washed extensively, eluted, and loaded on 10% polyacrylamide gels for SDS-PAGE. The GST tag and hexahistidine tag alone were used as negative controls to demonstrate the specificity of interaction. Ni-chelation-Sepharose and glutathione-Sepharose were used as additional negative controls. GST-ID (lane 3) and His-GRIM-12 (lane 9) bound to the glutathione-Sepharose and Ni-chelation-Sepharose, respectively (Fig. 13C). The two proteins interacted with each other when coincubated. Consequently, GST-ID was pulled down along with His-GRIM-12 by Ni-chelation-Sepharose (lane 8). Similarly, His-GRIM-12 was pulled down along with GST-ID by glutathione-Sepharose (lane 4). Neither Ni-chelation-Sepharose (lane 6) nor His tag alone (lane 11) interacted with GST-ID. Therefore, it was not pulled down along with them. Similarly, His-tag GRIM-12 did not interact with either glutathione-Sepharose (lane 2) or GST tag alone (lane 1). These




FIG. 10. Antisense expression of GRIM-12 interferes with TR expression. HeLa cells transfected with the pTKO1 or GRIM-12 episomes were stably selected with hygromycin B for 4 weeks as described in Materials and Methods. (A) Total RNA (40 μ g) from each cell line was used for Northern blotting. The blots were probed with 32 P-labeled GRIM-12. Solid and open arrowheads indicate the positions of antisense and sense GRIM-12 mRNAs, respectively. (B) Expression of TR protein in the antisense GRIM-12-transfected cells. Equal amounts of the cell extract (50 μ g) from the indicated cells were analyzed by Western blotting. Note the differences in expression of TR protein between the two cell types. (C) TR activity of the cells used in panels A and B. Cell extracts (20 μ g) were assayed for TR as described in the legend to Fig. 9. Each bar represents mean absorbance $\pm$ SE of triplicate determinations.

data show that the mutant and wild-type proteins interact with each other in vitro in the absence of other proteins.

GRIM-12 specifically mediates IFN-RA-induced death. We next examined whether ID also blocked the growth-inhibitory effects of other cytotoxic agents. For this purpose, cell clones expressing vector alone, FAD, or ID were treated with tumor necrosis factor alpha (TNF- α), etoposide, or vincristine and monitored for growth inhibition (Fig. 14). The cells were treated with concentrations of these drugs near their 50% inhibitory concentration. Growth of cells transfected with vector alone was strongly inhibited by all three agents. Overexpression of either the FAD or ID domain did not confer a growth advantage in the presence of these agents. Therefore,




FIG. 11. Expression of various functional domains of GRIM-12 (TR) in MCF-7 cells. (A) Proposed functional domains of GRIM-12 protein and their approximate sizes. N and C indicate the amino and carboxyl termini, respectively, of the native protein. aa, amino acids. (B) Northern blot analysis of total RNA (40 μ g) from various cell lines with the GRIM-12 probe. Labels above the panel indicate plasmids transfected into the cells. V, pCXN2 vector; FAD, FAD domain; NBD, NADPH binding domain; ID, interface domain; FL, full-length mRNA; DN, dominant negative mutants. The lanes contained comparable amounts of RNA as detected by the glyceraldehyde-3-phosphate dehydrogenase probe (data not shown).




FIG. 12. Effects of IFN- β (500 U/ml), RA (1 μ M), and their combination on the growth of MCF-7 cells expressing various domains of GRIM-12. (A) Effects of the single agents on the cell growth described in the legend to Fig. 10. (B) Effects of the IFN-RA combination on cell growth. Growth assays were performed as described in the legend to Fig. 1. Each bar represents the mean $\pm$ SE of six replicate determinations in the same experiment. UT, untransfected cells. Other notations are explained in the legend to Fig. 11B. Mean absorbance values for 0 and 100% growth, respectively, in this experiment are as follows: UT, 0.195 and 1.83; V, 0.210 and 2.30; FAD, 0.18 and 0.185; NBD, 0.207 and 0.211; ID, 0.17 and 1.83. (C) TR activity of the cells shown in panel B. Each bar shows the mean $\pm$ SE of triplicate determinations. Cell extracts (25 μ g) were assayed as described in Materials and Methods. (D) Effect of AZ on IFN-RA (IR)-induced cell death. MCF-7 cells were incubated with the indicated agents, and growth was measured after 6 days. Note the cell death in the IR column and its inhibition by AZ (10 μ M). Mean absorbance values for 0 and 100% growth are 0.186 and 1.52, respectively.

TNF- α , etoposide, and vincristine did not require GRIM-12 for inhibiting cell growth. These data suggest a specific participation of GRIM-12 in the IFN-RA-induced cell death pathway.

Effect of GRIM-12 overexpression on cell growth. Since the above experiments indicated that interference with TR expression and function prevents IFN-RA-induced cell death, we examined the effect of GRIM-12 overexpression on cell growth. GRIM-12 ORF cloned in pCXN2 vector was electroporated into MCF-7 cells, and G418-resistant clones were selected. A parallel control with the expression vector alone was also included. Multiple plates were used in the experiment. One set was stained with Giemsa to determine the colony number. Other plates were used to determine cell growth, mRNA expression, and enzyme assay. Although drug-resistant colonies formed in both cases, significantly fewer colonies formed in the case of GRIM-12-transfected cells (Fig. 15A). This result suggested that cells expressing the highest level of GRIM-12 died during selection. The surviving drug-resistant colonies from pCXN2 ($n = 1,000$)- and GRIM-12 ($n = 750$)-transfected plates were pooled separately, and their growth was monitored by the sulforhodamine B assay (60). The GRIM-12-transfected cells grew significantly slower than those transfected with the vector alone (Fig. 15B). To determine the expression of transfected gene, Northern blot analyses were performed with the RNAs derived from pCXN2- and GRIM-12-transfected cells. A 1.4-kb mRNA was seen only (Fig. 15C,

solid arrowhead) in the GRIM-12-transfected cells. A larger species of endogenous mRNA was also seen in pCXN2- and GRIM-12-transfected cells (open arrowhead). Enzyme assays revealed approximately 3.5-fold more enzyme activity in GRIM-12-transfected cells than in those that expressed the vector alone (Fig. 15D). We next examined whether GRIM-12-transfected cells were more sensitive to IFN-RA-induced cell death. Indeed, IFN-RA caused significantly higher cell death in GRIM-12-expressing cells than in those expressing the vector (Fig. 15E).

DISCUSSION

Although IFNs robustly suppress the growth of several leukemias, they are less effective against solid tumors like breast tumors and melanomas (18, 28). Our studies show that combination of IFN- α/β with RA, but not the single agents, causes cell death in vitro. At a comparable dosage, only IFN- α/β but not IFN- γ causes cell death in the presence of RA (Fig. 1), suggesting that these two cytokines use different mechanisms




FIG. 13. Binding of purified ID to GRIM-12 (TR) in vitro. ID and GRIM-12 were expressed as GST and histidine-tagged fusion proteins in *E. coli*. Pure proteins were obtained after two rounds of chromatography on glutathione-Sepharose or Ni-chelation-Sepharose columns. (A and B) Silver-stained SDS-PAGE gels (10% polyacrylamide) after purification of these proteins. Overexpression of fusion protein was performed by treating the cells with an inducer (IPTG). (C) Equimolar amounts of purified proteins were preincubated with each other before being subjected to chromatography on the indicated column. The presence or absence of the proteins in the incubation mixture is indicated by + and -, respectively. Affinity matrices used for separation after protein interaction are indicated above the arrows. After elution, the samples were loaded and separated by SDS-PAGE (10% polyacrylamide). Pure proteins (one-fifth of those in other lanes), without passing over the affinity matrices, were loaded in lanes 5 and 10. After separation, the samples were Western blotted with a TR-specific antibody. Western blotting was used to detect any nonspecific interactions between tags and fusion protein.




FIG. 14. Effects of other growth inhibitors on cells expressing various domains of GRIM-12. Cells were challenged with doses of etoposide, TNF- α , and vincristine near their IC_{50} , and growth assays were performed as in Fig. 1. Mean absorbance values for 0 and 100% growth, respectively, in this experiment are as follows: V, 0.19 and 2.15; FAD, 0.175 and 1.90; ID, 0.22 and 2.31. Other notations are explained in the legend to Fig. 12.

to exert antitumor actions. Since cell death induction by the IFN-RA combination is independent of cycle arrest (Fig. 2), it appears that different gene products regulate growth arrest and death activities. Interestingly, IFN-RA-induced death does not involve classic internucleosomal fragmentation of the genome, a hallmark of apoptosis (data not shown). A number of studies, including those with IFN- γ , have shown that internucleosomal DNA fragmentation is not obligatory for programmed cell death to occur (9, 11, 55, 56, 65). Taken together, these observations suggest that death regulation by IFNs involves hitherto undefined pathways.

Indeed, examination of two IFN-stimulated pathways that cause growth arrest or apoptosis (50, 59) indicated no significant changes in the levels and activities of PKR and RNase L during IFN-RA-induced cell death. In both cultured cells and regressing tumors, RNase L and PKR activities did not correlate with growth suppression (Fig. 3). No changes in the phosphorylation status of pRb or the levels of p53, Bcl2, or Bax occurred during death (data not presented). Consistent with these observations, IFNs induce cell death independently of p53 in several cell lines (11, 43). Recently, IFN- γ has been shown to induce interleukin-1 β -converting enzyme gene expression in HeLa cells that undergo apoptosis (7), indicating that caspases may be crucial for IFN- γ -induced cell death. Indeed, STAT1 is required for basal expression of certain caspases (31). However, IFN- γ alone or in combination with RA did not cause cytotoxicity in the cell lines used in this study (Fig. 1). Even though IFNs failed to induce the death of the human breast carcinoma cells used in our study, TNF- α did so rapidly (data not shown). Since TNF- α induces cell death by using caspases (5, 41), activation of caspases appears to be normal in these cells. Strikingly, a longer exposure to the IFN-RA combination (3 to 4 days) than to TNF- α (6 to 8 h) is required for death induction. Therefore, IFN- β -RA-induced cell death may differ from the known pathways and utilize some undefined gene products.

To identify the functionally relevant death-associated gene products, we used the antisense technical knockout strategy (12). In this approach, specific GRIM are inactivated by antisense gene products, thus providing a growth advantage to transfected cells in the presence of the IFN-RA combination. The library used in the present study was generated with the RNAs isolated from untreated cells as well as those treated

with the IFN-RA combination. Thus, genes expressed at all stages of the cell death process were included in the library without a bias for those expressed only after treatment. Because an IFN-stimulated promoter drives the expression of the antisense inserts, a functional JAK-STAT pathway is required (12). Therefore, antisense RNAs directed against the genes encoding IFN receptor chains, JAKs, or STATs cannot account for cell survival in the presence of IFN-RA. In fact, cDNAs corresponding to these products have not been rescued in our studies or in other studies (11). Consistent with the possibility that multiple gene products participate in IFN-RA-induced cell death, we have rescued at least 14 different cDNAs by this approach (data not shown). GRIM-12, the cDNA characterized in this study, protected cells from IFN-RA-induced death when expressed in antisense orientation (Fig. 4 and data not shown). Sequence analysis of this cDNA revealed that it was identical to the gene encoding human TR (16). The transcription of GRIM-12 mRNA was not induced in these cells by IFN-RA treatment. However, its expression was enhanced at a posttranscriptional level. The up regulation of the GRIM-12 protein level corresponded to an increase in its enzymatic




FIG. 15. Effect of GRIM-12 overexpression on cell growth. MCF-7 cells were transfected with comparable amounts of pCXN2 or GRIM-12 cloned in pCXN2 vector. The cells were selected for 4 weeks with G418. (A) One set of plates was stained with Giemsa to determine the number of colonies formed. The other was used for the experiments in panels B to E. (B) Growth of different cell types. Cell growth was compared after 6 days of growth by using the sulforhodamine B assay. Each bar represents the fold increase in cell number $\pm$ SEM of six samples. (C) Northern blot analysis of GRIM-12 mRNA expression. Open and solid arrowheads indicate the positions of the endogenous and transfected GRIM-12, respectively. (D) TR activity in the cells used in panels B and C. Mean absorbance values $\pm$ SE of triplicate determinations are shown. (E) Effect of IFN-RA. Equal numbers of indicated cells were exposed to IFN-RA (500 U/ml and 1 μ M) for 6 days. The growth assay was performed as described in the legend to Fig. 1. The percentage of dead cells corresponding to each untreated control was monitored. Each bar represents the mean $\pm$ SE of six samples. Mean absorbance values for 0 and 100% growth, respectively, for panels B and E are as follows: pCXN2, 0.21 and 1.407; GRIM-12, 0.23 and 1.08.

activity, which also reached its maximum during cell death. Thus, there appears to be a direct correlation between enzymatic activity and cell death. The relationship between inhibition of TR gene expression by antisense knockout and cell survival in long-term culture was established by the expression of antisense mRNA, suppression of TR expression (protein), and corresponding loss of enzyme activity in the cells that expressed antisense GRIM-12 (Fig. 10).

The observation that antisense mRNA conferred death resistance by ablating TR expression was further confirmed by using dominant negative inhibitors derived from GRIM-12 cDNA (Fig. 12B). Expression of the FAD domain (active site) alone did not confer significant resistance to IFN-RA-induced death. However, expression of the NBD and ID imparted resistance, with the latter conferring the greatest degree of resistance against IFN-RA-induced death. NBD may interfere with optimal activities of other death-associated redox enzymes by sequestering NADPH. Since the ID of TR is required to generate a functional dimeric enzyme, its overexpression may strongly inhibit enzyme activity and also cell death. The FAD domain does not significantly interfere with cell death because it may not inhibit enzymatic activity strongly. The differential sensitivity of transfectants to cell death was not due to a difference in the levels of endogenous TR and mutant domains of GRIM-12 (Fig. 11). Due to a lack of a specific antibody that detects all these mutants, we were unable to demonstrate the expression of the mutant proteins. However, enzyme assays revealed that overexpression of ID strongly interfered with enzymatic activity. They also suggest that inhibition of enzymatic activity is required for interference with death induction. It is likely that ID inhibits the activity by binding to the full-length enzyme, although the exact *in vivo* conformation of the mutant ID molecule is uncertain. Interaction of purified ID with full-length TR *in vitro* (Fig. 13) provides support for this hypothesis. The interaction between these proteins is not mediated by their respective expression tags, because tags alone do not bind to full-length TR or ID (Fig. 13C). More importantly, a direct role for TR in IFN-RA-mediated cell death was supported by several observations (Fig. 15). (i) Overexpression of GRIM-12 *per se* resulted in the formation of fewer colonies compared to control vector alone (13% less than the control value; i.e., cells expressing the highest level of GRIM-12 probably died during the isolation of stable cell lines). (ii) The clones that survived and expressed TR grew relatively slowly. (iii) Cell death was augmented by IFN-RA in GRIM-12-expressing cells compared to those expressing vector alone. (iv) A known activator (selenite) and an inhibitor (AZ) of TR activity augmented and suppressed IFN-RA induced cell death, respectively. The failure of ID to interfere with the growth-inhibitory actions of TNF- α , vincristine, and etoposide suggests a specific role for GRIM-12 (TR) in IFN-RA-inducible cell death (Fig. 14).

In mammalian cells, glutathione reductase and TR reduce their respective substrates, glutathione and Trx, to maintain the intracellular redox state. They then transfer electrons to several cellular transcription factors, including those involved in DNA synthesis. The TR-Trx system is highly conserved from *E. coli* to mammals. Trx, an ~11-kDa protein, has the conserved sequence Trp-Cys-Gly-Pro-Cys-Lys. Based on the ability of exogenous and transfected Trx to stimulate cell growth, it has been proposed that the TR-Trx system acts as a growth promoter (15). Trx is also known as adult T-cell-derived leukemic growth factor, because it has been isolated as a stimulant of leukemic cell growth (63). In contrast, results presented in this study and those of others (12) indicate that TR and Trx are growth inhibitors. Although Trx prevents apoptosis in murine

WEHI cells (2), it inhibited the growth of certain hepatoma cells (49). These conflicting observations raise the question of how a growth-promoting molecule participates in cell death. A major difference between our studies and others is the presence of selection pressure exerted by cytotoxic agents. Thus, in the absence of growth inhibitors, TR-Trx may participate in normal cell growth processes. However, in the presence of inhibitory pressure (e.g., from IFNs or IFN-RA), the TR-Trx system may activate factors that culminate in cell death. Furthermore, studies with overexpressed Trx might represent a supraphysiological condition, wherein Trx activates only pro-growth pathways. Unlike such studies, our studies and those of Deiss and Kimchi (12) lowered the physiological TR or Trx level to provide a growth advantage. That said, TR might also use substrates other than Trx for inducing death. Indeed, mammalian TR also reduces compounds like selenite, alloxan, vitamin K and 5,5'-dithiobis(2-nitrobenzoic acid) *in vitro* (4, 23, 24). Selenite has been shown to inhibit cell growth, and dietary selenium has been shown to reduce the incidence of tumors (61). Indeed, the addition of selenite to growth media augmented the IFN-RA-induced cell death compared to that in control cultures. Furthermore, selenite as a single agent also caused some growth inhibition compared to that in untreated cells in the present studies (data not shown). Based on these observations, we suggest that TR-Trx acts as a "yin-yang" regulatory system in growth control (20). In an analogous manner, depending on the physiologic status of the cell, the proto-oncogene *myc* can act as a growth promoter or as a mediator of cell death (21, 44). Irrespective of which mechanism is operative, our studies assign a novel function to TR in IFN-RA-induced death pathways.

Since IFN- α/β and IFN- γ use shared signal transducers (10) to regulate cellular functions, they may also use certain common pathways to inhibit cell growth. Thus, GRIM-12 (TR) and Trx (12) may represent converging points of the death pathway used by these closely related yet functionally distinct cytokines. More importantly, the choice of target (TR or Trx) activated during death induction appears to be influenced by the coactivating ligand. In our study, cell death was induced by a combination of IFN- β and RA, whereas in the earlier study it was IFN- γ alone (12). Despite these close similarities, other GRIMs are not identical to DAP (death-associated protein) genes induced by IFN- γ for killing the cells (30). Although IFN- α/β and IFN- γ use overlapping signal transduction pathways and induce similar downstream genes, each of them also induces unique cellular genes. Consequently, they may also induce different death programs. Thus, the cell growth-inhibitory actions of IFN- α/β and IFN- γ may not be identical.

The roles of oxidoreductases in growth control are less well appreciated, largely because they modify cellular substrates with groups that have a relatively short half-life (46). Unlike protein kinases, these enzymes do not add stable prosthetic groups to their substrates, thus making it difficult to assess their specific roles in growth or death processes. Although the downstream molecular events that mediate TR-Trx-induced growth inhibition or cell death are still unclear, genetic studies by ourselves and others illustrate novel mechanisms of cell death involving oxidoreductases. One level at which Trx may influence the IFN-induced inhibitory growth pathways is via modulation of JAK function. Recent studies have shown that the redox status of JAKs is essential for their activity (14). The reduced state promotes JAK activity, and the oxidized state inhibits it. Expression of the TR dominant negative inhibitors may alter the redox state of JAKs and therefore confer resistance to IFN-RA treatment. Similarly, suppression of Trx levels may ablate growth-inhibitory effects of IFN- γ (12). Inter-

ference with JAK function may inhibit the ability of IFNs to induce growth-regulatory genes such as interleukin-1 β -converting enzyme or WAF/Cip1 (7, 8) and therefore may enhance cell survival. Oxidative conditions activate NF- κ B, which induces the anti-apoptotic gene products (1). Indeed, treatment of cells with Trx inhibits the DNA binding of NF- κ B and cotransfection of Trx gene suppresses NF- κ B-dependent gene expression (29, 54). Dominant negative inhibition of TR function may also activate the NF- κ B-dependent cell survival program. Therefore, these cells may become resistant to IFN-RA. Future studies should resolve these questions.

Lastly, a formal link exists between TR and p53 tumor suppressor activity. For example, human p53 normally induces gene expression and growth inhibition in *Schizosaccharomyces pombe* but fails to exert these effects in mutants lacking TR (6). Consistent with a role for TR-Trx in growth control, deletion of Trx genes in yeast leads to an increase in the mitotic cycle and DNA replication rates (40). TR also inhibited gene induction from *Mlu*I cell cycle (MCB) boxes present in the promoters of genes that regulate yeast cell growth (35). More importantly, a number of p53-induced cell death gene products are oxidoreductases (45). These observations underscore the importance of redox factors in cell growth inhibition and death. Finally, despite the abrogation of cell death by ID mutant of TR, ~60% of the IFN-RA-induced growth inhibition still occurred. One explanation of this observation is that ID of GRIM-12 may be an inefficient repressor of IFN-RA-induced growth inhibition. Consequently, near 100% growth did not occur in these cells. If that were the situation, a strong inhibitor of TR should completely inhibit IFN-RA-induced growth-suppressive actions. Although AZ, a known inhibitor of TR (52), prevented IFN-RA-induced cell death, it failed to counteract the growth-inhibitory effects completely. Thus, a genetic and a chemical inhibitor of TR both block the IFN-RA-induced death pathway. The fact that the IFN-RA combination continues to inhibit cell growth despite TR inhibition suggests the induction of other GRIM-12 (TR)-independent cell growth-suppressive pathways. Since overexpression of GRIM-12 alone does not kill a majority of transfected cells, ligand-induced posttranslational modifications and expression of other IFN-RA-induced death regulators are necessary for death to occur, in addition to an increase in TR levels. Indeed, isolation of other GRIMs supports this hypothesis.

ACKNOWLEDGMENTS

We thank Ernest Borden, Eric Angell, and Wang Ling for helpful suggestions, and we thank Adi Kimchi and Garth Powis for providing pTKO1 and the TR-specific antibody, respectively.

These studies were supported by grants from the National Cancer Institute to D.V.K. E.R.H. thanks the US-Army Breast Cancer Program for a graduate fellowship. D.J.L. is a fellow of Karl C. Dod foundation.

E.R.H. and M.B. contributed equally to this study.

REFERENCES

- Baichwal, V. R., and P. A. Baeuerle. 1997. Activate NF-kappa B or die? *Curr. Biol.* 7:R94-R96.
- Baker, A., C. M. Payne, M. M. Briehl, and G. Powis. 1997. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. *Cancer Res.* 57:5162-5167.
- Barber, G. N., M. Wambach, S. Thompson, R. Jagus, and M. G. Katze. 1995. Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. *Mol. Cell. Biol.* 15:3138-3146.
- Bjornstedt, M., S. Kumar, and A. Holmgren. 1995. Selenite and selenodiglutathione: reactions with thioredoxin systems. *Methods Enzymol.* 252:209-219.
- Boldin, M. P., T. M. Goncharov, Y. V. Goltsev, and D. Wallach. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell* 85:803-815.
- Casso, D., and D. Beach. 1996. A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast *Schizosaccharomyces pombe*. *Mol. Gen. Genet.* 252:518-529.
- Chin, Y. E., M. Kitagawa, K. Kuida, R. A. Flavell, and X. Y. Fu. 1997. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. *Mol. Cell. Biol.* 17:5328-5337.
- Chin, Y. E., M. Kitagawa, W. C. Su, Z. H. You, Y. Iwamoto, and X. Y. Fu. 1996. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. *Science* 272:719-722.
- Cohen, G. M., X. M. Sun, R. T. Snowden, D. Dinsdale, and D. N. Skilleter. 1992. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. *Biochem. J.* 286:331-334.
- Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264:1415-1421.
- Deiss, L. P., E. Feinstein, H. Berissi, O. Cohen, and A. Kimchi. 1995. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. *Genes Dev.* 9:15-30.
- Deiss, L. P., and A. Kimchi. 1991. A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. *Science* 252:117-120.
- Dong, B., and R. H. Silverman. 1995. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. *J. Biol. Chem.* 270:4133-4137.
- Duhe, R. J., G. A. Evans, R. A. Erwin, R. A. Kirken, G. W. Cox, and W. L. Farrar. 1998. Nitric oxide and thiol redox regulation of Janus kinase activity. *Proc. Natl. Acad. Sci. USA* 95:126-131.
- Gallegos, A., J. R. Gasdaska, C. W. Taylor, G. D. Paine-Murrieta, D. Goodman, P. Y. Gasdaska, M. Berggren, M. M. Briehl, and G. Powis. 1996. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. *Cancer Res.* 56:5765-5770.
- Gasdaska, P. Y., J. R. Gasdaska, S. Cochran, and G. Powis. 1995. Cloning and sequencing of a human thioredoxin reductase. *FEBS Lett.* 373:5-9.
- Glass, C. K., D. W. Rose, and M. G. Rosenfeld. 1997. Nuclear receptor coactivators. *Curr. Opin. Cell Biol.* 9:222-232.
- Gutterman, J. U. 1994. Cytokine therapeutics: lessons from interferon a. *Proc. Natl. Acad. Sci. USA* 91:1198-1205.
- Hassel, B. A., A. Zhou, C. Sotomayor, A. Maran, and R. H. Silverman. 1993. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. *EMBO J.* 12:3297-3304.
- Heppell-Parton, A., A. Cahn, A. Bench, N. Lowe, H. Lehrach, G. Zehetner, and P. Rabbitts. 1995. Thioredoxin, a mediator of growth inhibition, maps to 9q31. *Genomics* 26:379-381.
- Hermeking, H., and D. Eick. 1994. Mediation of c-Myc-induced apoptosis by p53. *Science* 265:2091-2093.
- Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. *J. Mol. Biol.* 26:365-369.
- Holmgren, A., and M. Bjornstedt. 1995. Thioredoxin and thioredoxin reductase. *Methods Enzymol.* 252:199-208.
- Holmgren, A., and C. Lyckeberg. 1980. Enzymatic reduction of alloxan by thioredoxin and NADPH-thioredoxin reductase. *Proc. Natl. Acad. Sci. USA* 77:5149-5152.
- Holtshchke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. Waring, M. F. Bachmann, R. M. Zinkernagel, H. C. Morse, K. Ozato, and I. Horak. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* 87:307-317.
- Hong, W. K., and L. M. Itri. 1994. Retinoids and human cancer, p. 597-630. In M. B. Sporn, A. B. Roberts, and D. S. Goodman (ed.), *The retinoids: biology, chemistry and medicine*, 2nd ed. Raven Press, New York, N.Y.
- Kalvakolanu, D. V., S. K. Bandyopadhyay, M. L. Harter, and G. C. Sen. 1991. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. *Proc. Natl. Acad. Sci. USA* 88:7459-7463.
- Kalvakolanu, D. V., and E. C. Borden. 1996. An overview of the interferon system: signal transduction and mechanisms of action. *Cancer Invest.* 14:25-53.
- Kim, I. Y., and T. C. Stadtman. 1997. Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. *Proc. Natl. Acad. Sci. USA* 94:12904-12907.
- Kimchi, A. 1998. DAP genes: novel apoptotic genes isolated by a functional approach to gene cloning. *Biochim. Biophys. Acta* 1377:F13-F33.
- Kumar, A., M. Commene, T. W. Flickinger, C. M. Horvath, and G. R. Stark. 1997. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. *Science* 278:1630-1632.
- Kumar, R., and I. Atlas. 1992. Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. *Proc. Natl. Acad. Sci. USA* 89:6599-6603.
- Laurent, A. G., B. Krust, J. Galabru, J. Svab, and A. G. Hovanessian. 1985. Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in

- human cells. *Proc. Natl. Acad. Sci. USA* **82**:4341-4345.
34. Lindner, D. J., E. C. Borden, and D. V. Kalvakolanu. 1997. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. *Clin. Cancer Res.* **3**:931-937.
35. Machado, A. K., B. A. Morgan, and G. F. Merrill. 1997. Thioredoxin reductase-dependent inhibition of MCB cell cycle box activity in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **272**:17045-17054.
36. Mangelsdorf, D. J., and R. M. Evans. 1995. The RXR heterodimers and orphan receptors. *Cell* **83**:841-850.
37. Meissner, P. S., W. P. Sisk, and M. L. Berman. 1987. Bacteriophage lambda cloning system for the construction of directional cDNA libraries. *Proc. Natl. Acad. Sci. USA* **84**:4171-4175.
38. Miranda-Vizuete, A., and G. Spyrou. 1997. The novel oxidoreductase KDRF (KM-102-derived reductase-like factor) is identical with human thioredoxin reductase. *Biochem. J.* **325**:287-288.
39. Moore, D. M., D. V. Kalvakolanu, S. M. Lippman, J. J. Kavanagh, W. K. Hong, E. C. Borden, M. Paredes-Espinoza, and I. H. Krakoff. 1994. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. *Semin. Hematol.* **31**:31-37.
40. Muller, E. G. 1991. Thioredoxin deficiency in yeast prolongs S phase and shortens the G1 interval of the cell cycle. *J. Biol. Chem.* **266**:9194-9202.
41. Muzio, M., A. M. Chinnaiyan, F. C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni, C. Scalfidi, J. D. Bretz, M. Zhang, R. Gentz, M. Mann, P. H. Krammer, M. E. Peter, and V. M. Dixit. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. *Cell* **85**:817-827.
42. Nolan-Sorden, N. L., K. Lesiak, B. Bayard, P. F. Torrence, and R. H. Silverman. 1990. Photochemical crosslinking in oligonucleotide-protein complexes between a bromine-substituted 2-5A analog and 2-5A-dependent RNase by ultraviolet lamp or laser. *Anal. Biochem.* **184**:298-304.
43. Ossina, N. K., A. Cannas, V. C. Powers, P. A. Fitzpatrick, J. D. Knight, J. R. Gilbert, E. M. Shekhtman, L. D. Tomei, S. R. Umansky, and M. C. Kiefer. 1997. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. *J. Biol. Chem.* **272**:16351-16357.
44. Packham, G., and J. L. Cleveland. 1995. c-Myc and apoptosis. *Biochim. Biophys. Acta* **1242**:11-28.
45. Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein. 1997. A model for p53-induced apoptosis. *Nature* **389**:300-305.
46. Powis, G., M. Briehl, and J. Oblong. 1995. Redox signalling and the control of cell growth and death. *Pharmacol. Ther.* **68**:149-173.
47. Raveh, T., A. G. Hovanessian, E. F. Meurs, N. Sonenberg, and A. Kimchi. 1996. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. *J. Biol. Chem.* **271**:25479-25484.
48. Resnitzky, D., N. Tiefenbrun, H. Berissi, and A. Kimchi. 1992. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. *Proc. Natl. Acad. Sci. USA* **89**:402-406.
49. Rubartelli, A., N. Bonifaci, and R. Sitia. 1995. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. *Cancer Res.* **55**:675-680.
50. Samuel, C. E., K. L. Kuhen, C. X. George, L. G. Ortega, R. Rende-Fournier, and H. Tanaka. 1997. The PKR protein kinase—an interferon-inducible regulator of cell growth and differentiation. *Int. J. Hematol.* **65**:227-237.
51. Savinova, O., and R. Jagus. 1997. Use of vertical slab isoelectric focusing and immunoblotting to evaluate steady-state phosphorylation of eIF2 alpha in cultured cells. *Methods* **11**:419-425.
52. Schallreuter, K. U., and J. M. Wood. 1987. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. *Cancer Lett.* **36**:297-305.
53. Schmidt, M., S. Nagel, J. Proba, C. Thiede, M. Ritter, J. F. Waring, F. Rosenbauer, D. Huhn, B. Wittig, I. Horak, and A. Neubauer. 1998. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. *Blood* **91**:22-29.
54. Schulze-Osthoff, K., H. Schenk, and W. Droge. 1995. Effects of thioredoxin on activation of transcription factor NF-kappa B. *Methods Enzymol.* **252**:253-264.
55. Schulze-Osthoff, K., H. Walczak, W. Droge, and P. H. Krammer. 1994. Cell nucleus and DNA fragmentation are not required for apoptosis. *J. Cell Biol.* **127**:15-20.
56. Schwartz, L. M., S. W. Smith, M. E. Jones, and B. A. Osborne. 1993. Do all programmed cell deaths occur via apoptosis? *Proc. Natl. Acad. Sci. USA* **90**:980-984.
57. Scorsone, K. A., R. Panniers, A. G. Rowlands, and E. C. Henshaw. 1987. Phosphorylation of eukaryotic initiation factor 2 during physiological stresses which affect protein synthesis. *J. Biol. Chem.* **262**:14538-14543.
58. Sen, G. C., and R. M. Ransohoff. 1997. Transcriptional regulation in the interferon system. Chapman & Hall and Landes Bioscience, Austin, Tex.
59. Silverman, R. H. 1997. 2-5A dependent RNase L: a regulated endoribonuclease in the interferon system, p. 515-551. *In* G. D'Alessio and J. F. Riordan (ed.), *Ribonucleases: structure and functions*. Academic Press, Inc., New York, N.Y.
60. Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. *J. Natl. Cancer Inst.* **82**:1107-1112.
61. Spyrou, G., M. Bjornstedt, S. Skog, and A. Holmgren. 1996. Selenite and selenate inhibit human lymphocyte growth via different mechanisms. *Cancer Res.* **56**:4407-4412.
62. Studzinski, G. P. (ed.). 1995. *Cell growth and apoptosis: a practical approach*. IRL Press, Oxford, United Kingdom.
63. Tagaya, Y., Y. Maeda, A. Mitsui, N. Kondo, H. Matsui, J. Hamuro, N. Brown, K. Arai, T. Yokota, H. Wakasugi, et al. 1989. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin: possible involvement of dithiol-reduction in the IL-2 receptor induction. *EMBO J.* **8**:757-764.
64. Taniguchi, T., M. S. Lamphier, and N. Tanaka. 1997. IRF1: the transcription factor linking interferon response and oncogenesis. *Biochim. Biophys. Acta* **1333**:M9-M17.
65. Ucker, D. S., P. S. Obermiller, W. Eckhart, J. R. Apgar, N. A. Berger, and J. Meyers. 1992. Genome digestion is a dispensable consequence of physiological cell death mediated by cytotoxic T lymphocytes. *Mol. Cell. Biol.* **12**:3060-3069.
66. Willman, C. L., C. E. Sever, M. G. Pallavicini, H. Harada, N. Tanaka, M. L. Slovak, H. Yamamoto, K. Harada, T. C. Meeker, A. F. List, and T. Taniguchi. 1993. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. *Science* **259**:968-971.

Lindner, D. J., E. R. Hofmann, et al. (1999). "Overexpression of thioredoxin reductase (GRIM-12) enhances antiproliferative and apoptotic activity of IFN- β and tamoxifen in MCF-7 cells." Proceedings of the American Association for Cancer Research **40**: 223.

We previously reported that IFN- β in combination with tamoxifen (TAM) is a more potent growth suppressor of human tumor cell growth *in vitro* and *in vivo* compared to single agents. Our recent study showed that the cell death effects of the IFN- β /retinoic acid (RA) combination are mediated by thioredoxin reductase (TR), also known as GRIM-12. In this study, annexin-V binding indicated apoptosis was induced by both combinations. Overexpression of GRIM-12 caused MCF-7 cell death and enhanced susceptibility to either IFN- β /TAM- or IFN- β /RA. Dominant negative inhibitors directed against TR inhibited death induction. A TR enzymatic inhibitor (azeleic acid) caused growth promotion in the presence of either combination. Treatment with caspase inhibitors I or III partially inhibited antiproliferative activity and partially blocked apoptosis induced by both combinations. These effects were more pronounced in MCF-7 cells overexpressing TR. Hence, the pathways leading to growth inhibition and apoptotic cell death following IFN- β /TAM or IFN- β /RA appears to involve common mediators.

Lindner, D. J., E. R. Hofmann, et al. (1999). "Overexpression of thioredoxin reductase (GRIM-12) enhances antiproliferative and apoptotic activity of IFN- β and tamoxifen in MCF-7 cells." Invited Speaker.

We previously reported that IFN- β in combination with tamoxifen (TAM) is a more potent growth suppressor of human tumor cell growth *in vitro* and *in vivo* compared to single agents. Our recent study showed that the cell death effects of the IFN- β /retinoic acid (RA) combination are mediated by thioredoxin reductase (TR), also known as GRIM-12. In this study, annexin-V binding indicated apoptosis was induced by both combinations. Overexpression of GRIM-12 caused MCF-7 cell death and enhanced susceptibility to either IFN- β /TAM- or IFN- β /RA. Dominant negative inhibitors directed against TR inhibited death induction. A TR enzymatic inhibitor (azeleic acid) caused growth promotion in the presence of either combination. Treatment with caspase inhibitors I or III partially inhibited antiproliferative activity and partially blocked apoptosis induced by both combinations. These effects were more pronounced in MCF-7 cells overexpressing TR. Hence, the pathways leading to growth inhibition and apoptotic cell death following IFN- β /TAM or IFN- β /RA appears to involve common mediators.

A GENETIC METHOD IDENTIFIES THIOREDOXIN REDUCTASE AS A MEDIATOR OF INTERFERON AND RETINOIC ACID INDUCED CELL DEATH

Authors: Edward R. Hofmann, Madan M. Boyanapalli, Daniel J. Lindner, Xiao Weihua and Dhan V. Kalvakolanu

Interferons (IFNs) and retinoic acid (RA) are potent biological response modifiers that inhibit transformed cell growth. In tumor cells resistant to either IFN or RA, combination of both agents causes stronger growth inhibition. Using athymic nude mouse models and in vitro systems we have shown that IFN- γ /RA combination causes death of human breast carcinoma cells. Since we could not find a correlation between expression of known regulators and cell death, we employed the antisense technical knock-out strategy to isolate genes that participate in IFN/RA induced death pathways. We prepared total cell cDNA libraries from breast tumor cells treated with IFN/RA combination and cloned the inserts in antisense orientation into episomal vector pTKO1. Following transfection of these libraries the breast tumor cells were selected for resistance to IFN/RA induced cell death. Using this technique we have isolated several candidate genes termed Genes associated with Retinoid IFN induced Mortality (GRIM). In this study, we have characterized one of these genes, GRIM-12. Sequence analysis revealed that GRIM-12 was identical to human thioredoxin reductase (TR). IFN/RA combination stimulates the post-transcriptional expression of GRIM-12 (TR). Cells expressing dominant negative mutants derived from GRIM-12 failed to die in response to IFN/RA combination. The enzymatic activity of TR was essential for mediating cell death. Consistent with this, cofactors and inhibitors of TR activity promoted and suppressed IFN/RA induced cell death respectively. A previous study also identified thioredoxin (Trx) as a mediator of IFN- γ induced cell death. Our results and those of others identify a novel death mediating function for TR:Trx system in IFN/RA induced death pathways.



MULTIPLE EFFECTS OF γ -IFN ON GENES ASSOCIATED WITH ANTIGEN PROCESSING AND PRESENTATION IN NORMAL AND TRANSFORMED CELLS.

Sharon Vigodman-Fromm, Sigal Winograd, and Rachel Ehrlich, Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel.

MHC class I molecules are polymorphic, integral membrane proteins that bind a diverse group of peptides derived from endogenous antigens and display these peptides for recognition by cytotoxic T-lymphocytes. This mechanism enables the immune system to control infectious diseases and the growth of tumor cells. Malignant transformation often results in suppression of one or more of the genes that are associated with antigen processing, assembly and cell surface expression of class I complexes. In primary embryonal cells transformation with adenovirus 12 results in complete suppression of expression of the peptide transporter 2 (TAP2) gene, as well as of the proteasomal subunits, LMP2 and LMP7, while the expression of β 2m, class I heavy chain, and TAP1 genes are partially suppressed. A complete restoration of cell surface expression of class I MHC complexes can be achieved by treatment of the cells with γ -IFN. We are currently showing that a full reconstitution of TAP2 and class I heavy chain gene expression is essential for this restoration. A Threshold level of peptides and class I heavy chains has to be surpassed in order to achieve efficient assembly of class I complexes. In addition, γ -IFN significantly stabilizes class I MHC complexes and induces proteasome-mediated degradation of nascent (misfolded) class I heavy chains. The fact that class I complex assembly appears to be also highly inefficient in certain "normal" cell lines might be of a major *in vivo* obstacle for the elimination of transformed or virus-infected cells by CTL especially in view of the fact that the level of class I gene transcription is often down-regulated in cancer cells and/or that assembly of class I MHC complexes can be subverted by virus-encoded proteins. In these cases γ -IFN plays a major role in reconstituting specific immune responses.

160

Expression of cyclin-dependent kinase inhibitors p27, p21, p16 in human tumour cells Me 180 after treatment with TNF α and Interferon γ

Heinz BAISCH

Institute of Biophysics and Radiobiology, University of Hamburg, Martinistraße 52, D-20246 Hamburg, Germany

The tumour infiltrating macrophages release a variety of cytokines, which may affect the cell kinetics of the tumour cells. We have studied the effects of TNF α and Interferon (IFN γ) on proteins involved in cell cycle regulation. The cyclin-dependent kinase inhibitors (CKI) p27-Kip1, p21-Cip1, and p16-Ink4 were measured by flow cytometry in the human tumour cell line Me 180 after treatment with TNF α and IFN γ . All 3 inhibitors were expressed in all phases of the cell cycle. In normal fibroblasts the p27 level increased when the cells grew to confluence. In contrast, the p27 level decreased in Me 180 tumour cells when becoming confluent.

Single treatment of cells with TNF α or IFN γ maintained or slightly increased the level of CKI, whereas it decreased in control cells. A combination of both cytokines, however, induced a strong increase of all 3 CKIs. This increase was found in whole cells, and to lesser degree in cell nuclei. The cyclin E level, on the other hand, remained nearly constant in cell nuclei, only in whole cells it increased slightly. The increase of cyclin D1 level was much less than that of the CKI, in cell nuclei only a 2.5 fold increase was seen after 72 h treatment with TNF α and IFN γ . The cells which were detached from the bottom of the culture flask generally showed much lower cyclins as well as CKI levels than the attached vital cells and even lower levels than the control cells. These floating cells were identified as apoptotic by the Acridine Orange acidic method. Preliminary immun-precipitation experiments confirmed that p27 is attached to cyclin E and to cdk2. It has to be shown if p27 (and p16, p21) induced by the cytokines form the same complexes. Previous experiments had shown that IFN γ stopped transit through the cell cycle whereas TNF α detached many cells from the monolayer, which became apoptotic. The CKIs are known to be inhibitors in cell cycle progression, they may also be involved in induction of apoptosis.

414

IDENTIFICATION OF GENES DOWNREGULATED IN MICE WITH LYMPHOTOXIN DEFICIENCY

Alexander Shakhov^{1,2}, Ilya Lyakhov^{1,3} and Sergei A. Nedospasov^{1,3}

¹IRSP, SAIC Frederick and LMI, DBS, NCI-FCRDC, Frederick MD, USA;

²Institute of Toxicology, ETH and University of Zurich, Switzerland;

³Belozersky Institute of Physico-Chemical Biology, Moscow State University and Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.

Spleens of lymphotoxin (LT) deficient mice reveal defects in organization, including the lack of follicular dendritic cell network and marginal zone, poor T-B cell area separation and failure to develop germinal centers. These defects can be partially restored by bone marrow or spleen cells transfers from the wild-type (WT) mice, suggesting that the maintenance of proper spleen organization is an active process, associated with the expression of certain genes in response to LT signaling. In order to identify genes associated with mutant phenotype subtractive cDNA cloning, differential display and hybridizations with the poor man gene arrays have been applied to splenocytes of the LT α -deficient mice and their littermate WT controls. We have identified a number of known and novel sequences whose expression was substantially decreased in spleens of knock-out (KO) mice. Such sequences included genes encoding heavy chains of IgA and IgG, correlating with IgA and IgG deficiency previously reported for LT α KO mice. Other cloned gene products included scavenger receptor MARCO (specific for macrophages of the marginal zone), bone marrow stromal antigen BST-1, clusterin, chemokine CP-10 as well as several putative components of neutrophil granules. Finally, by subtractive cloning we ...have identified a novel homologue of secretory type phospholipase A2 which in WT mice is preferentially expressed in lymphoid tissues, including lymph nodes. (Funded in part by NCI, NIH Contract No. NO1-CO-56000).

IDENTIFICATION OF THIOREDOXIN REDUCTASE AS A POTENTIAL MEDIATOR OF INTERFERON- β AND RETINOIC ACID INDUCED CELL DEATH.

Hofmann, E.R., Boyanapalli, M., Lindner, D.J., Weihua, X. Kalvakolanu, D.V.

Interferons (IFN) and retinoids are powerful biological response modifiers. Although each are effective growth inhibitors of certain transformed cell lines, as single agents their efficacy against several tumors is limited. However, when used in combination they synergistically inhibit the growth of several tumors. Substantial evidence has been found that shows a combination of IFN- β /retinoic acid (RA) inhibits the growth of a variety of breast tumors both *in vitro* and *in vivo*. More importantly, in several breast tumor cell lines, IFN- β /RA combination treatment resulted in cell death. In order to better understand the mechanisms of growth inhibition, it is important to identify the gene products that lead to the observed cell death/growth arrest. Preliminary studies found that no correlation could be made between the induced cell death with known antitumor gene products upon treatment with IFN- β /RA. Data suggest that this observed cell death may be due to a novel or other unimplicated gene product(s). Therefore, we have employed an antisense knockout approach to identify the gene products that mediate cell death and have isolated several Genes associated with Retinoid-IFN Induced Mortality (GRIM). In this investigation we have characterized one of the GRIM cDNAs, GRIM-12. Sequence analysis revealed that GRIM-12 was identical to human thioredoxin reductase (TR). TR is post-transcriptionally induced by IFN/RA combination in human breast carcinoma cells. Dominant negative inhibitors directed against TR inhibit its cell death inducing functions. Interference with TR enzymatic activity led to growth promotion in the presence of IFN/RA combination. Thus, these studies identify a novel function for TR in cell growth regulation.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

5 JUN 2001

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports. Request the limited distribution statement for reports on the enclosed list be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl



PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

DAMD17-94-J-4413	ADB261602
DAMD17-96-1-6112	ADB233138
DAMD17-96-1-6112	ADB241664
DAMD17-96-1-6112	ADB259038
DAMD17-97-1-7084	ADB238008
DAMD17-97-1-7084	ADB251635
DAMD17-97-1-7084	ADB258430
DAMD17-98-1-8069	ADB259879
DAMD17-98-1-8069	ADB259953
DAMD17-97-C-7066	ADB242427
DAMD17-97-C-7066	ADB260252
DAMD17-97-1-7165	ADB249668
DAMD17-97-1-7165	ADB258879
DAMD17-97-1-7153	ADB248345
DAMD17-97-1-7153	ADB258834
DAMD17-96-1-6102	ADB240188
DAMD17-96-1-6102	ADB257406
DAMD17-97-1-7080	ADB240660
DAMD17-97-1-7080	ADB252910
DAMD17-96-1-6295	ADB249407
DAMD17-96-1-6295	ADB259330
DAMD17-96-1-6284	ADB240578
DAMD17-96-1-6284	ADB259036
DAMD17-97-1-7140	ADB251634
DAMD17-97-1-7140	ADB259959
DAMD17-96-1-6066	ADB235510
DAMD17-96-1-6029	ADB259877
DAMD17-96-1-6020	ADB244256
DAMD17-96-1-6023	ADB231769
DAMD17-94-J-4475	ADB258846
DAMD17-99-1-9048	ADB258562
DAMD17-99-1-9035	ADB261532
DAMD17-98-C-8029	ADB261408
DAMD17-97-1-7299	ADB258750
DAMD17-97-1-7060	ADB257715
DAMD17-97-1-7009	ADB252283
DAMD17-96-1-6152	ADB228766
DAMD17-96-1-6146	ADB253635
DAMD17-96-1-6098	ADB239338
DAMD17-94-J-4370	ADB235501
DAMD17-94-J-4360	ADB220023
DAMD17-94-J-4317	ADB222726
DAMD17-94-J-4055	ADB220035
DAMD17-94-J-4112	ADB222127
DAMD17-94-J-4391	ADB219964
DAMD17-94-J-4391	ADB233754